Document:

exv10w2

Exhibit 10.2

Development and License Agreement

Between

NuPathe Inc.

and

LTS Lohmann Therapie-Systeme AG

Confidential treatment requested under 17 C.F.R. §§ 200.80(b)(4) and 230.406. The
confidential portions of this exhibit have been omitted and are marked accordingly. The
confidential portions have been filed separately with the Securities and Exchange Commission
pursuant to the Confidential Treatment Request.

1

 

TABLE OF CONTENTS

(continued)

	 	 	 	 	 
	 	 	Page	 
	Article I. Definitions
	 	 	7	 
	 
	 	 	 	 
	1.01 Introduction
	 	 	7	 
	 
	 	 	 	 
	1.02 “Active Principle”
	 	 	7	 
	 
	 	 	 	 
	1.03 “Active Principle Specifications”
	 	 	7	 
	 
	 	 	 	 
	1.04 “Affiliate”
	 	 	7	 
	 
	 	 	 	 
	1.05 “Agreement”
	 	 	7	 
	 
	 	 	 	 
	1.06 “Annex”
	 	 	8	 
	 
	 	 	 	 
	1.07 “cGMP”
	 	 	8	 
	 
	 	 	 	 
	1.08 “Clinical Samples”
	 	 	8	 
	 
	 	 	 	 
	1.09 “Commercially Reasonable Efforts”
	 	 	8	 
	 
	 	 	 	 
	1.10 “Defective”
	 	 	8	 
	 
	 	 	 	 
	1.11 “Development Committee”
	 	 	9	 
	 
	 	 	 	 
	1.12 “Development Work”
	 	 	9	 
	 
	 	 	 	 
	1.13 “Development Plan”
	 	 	9	 
	 
	 	 	 	 
	1.14 “FDA”
	 	 	9	 
	 
	 	 	 	 
	1.15 “Iontophoretic Components”
	 	 	9	 
	 
	 	 	 	 
	1.16 “LTS Know How”
	 	 	10	 
	 
	 	 	 	 
	1.17 “LTS Intellectual Property”
	 	 	10	 
	 
	 	 	 	 
	1.18 “LTS Patents”
	 	 	10	 
	 
	 	 	 	 
	1.19 “Major Market Country”
	 	 	10	 
	 
	 	 	 	 
	1.20 “Manufacturing Agreement”
	 	 	10	 
	 
	 	 	 	 
	1.21 “NuPathe Know How”
	 	 	10	 
	 
	 	 	 	 
	1.22 “NuPathe Intellectual Property”
	 	 	10	 
	 
	 	 	 	 
	1.23 “Patents”
	 	 	11	 
	 
	 	 	 	 
	1.24 “Product”
	 	 	11	 
	 
	 	 	 	 
	1.25 “Party”
	 	 	11	 
	 
	 	 	 	 
	1.26 “Project”
	 	 	11	 
	 
	 	 	 	 
	1.27 “Quality Agreement”
	 	 	11	 
	 
	 	 	 	 
	1.28 “Report”
	 	 	11	 

2

 

TABLE OF CONTENTS

(continued)

	 	 	 	 	 
	 	 	Page	 
	1.29 “Specifications”
	 	 	12	 
	 
	 	 	 	 
	1.30 “Sublicensee”
	 	 	12	 
	 
	 	 	 	 
	1.31 “Territory”
	 	 	12	 
	 
	 	 	 	 
	1.32 Interpretation
	 	 	12	 
	 
	 	 	 	 
	Article II. Contribution of LTS
	 	 	13	 
	 
	 	 	 	 
	2.01 LTS Contribution
	 	 	13	 
	 
	 	 	 	 
	2.02 Report
	 	 	13	 
	 
	 	 	 	 
	2.03 Clinical Samples
	 	 	13	 
	 
	 	 	 	 
	2.04 Timelines
	 	 	14	 
	 
	 	 	 	 
	2.05 Implementation of the Project
	 	 	14	 
	 
	 	 	 	 
	2.06 LTS’ Support of Registration
	 	 	14	 
	 
	 	 	 	 
	2.07 Audit at LTS
	 	 	15	 
	 
	 	 	 	 
	2.08 Establishment Registration/Device Listing
	 	 	15	 
	 
	 	 	 	 
	Article III. Contributions of NuPathe
	 	 	15	 
	 
	 	 	 	 
	3.01 NuPathe Cooperation
	 	 	15	 
	 
	 	 	 	 
	3.02 Active Principle Supply
	 	 	15	 
	 
	 	 	 	 
	3.03 Active Principle Data
	 	 	16	 
	 
	 	 	 	 
	3.04 Evaluating Results
	 	 	16	 
	 
	 	 	 	 
	3.05 Iontophoresis Components
	 	 	17	 
	 
	 	 	 	 
	3.06 Clinical Trials
	 	 	17	 
	 
	 	 	 	 
	3.07 Registration of Products
	 	 	17	 
	 
	 	 	 	 
	3.08 Upgrade to the LTS’ facility
	 	 	17	 
	 
	 	 	 	 
	Article IV. Involvement of Third Parties
	 	 	18	 
	 
	 	 	 	 
	4.01 Involvement of Third Parties — General
	 	 	18	 
	 
	 	 	 	 
	4.02 Involvement of Third Parties by LTS
	 	 	18	 
	 
	 	 	 	 
	4.03 Involvement of Third Parties by NuPathe
	 	 	19	 
	 
	 	 	 	 
	Article V. Development Committee
	 	 	20	 
	 
	 	 	 	 
	5.01 Development Committee
	 	 	20	 
	 
	 	 	 	 
	5.02 Control over Project
	 	 	21	 

3

 

TABLE OF CONTENTS

(continued)

	 	 	 	 	 
	 	 	Page	 
	5.03 Meetings
	 	 	21	 
	 
	 	 	 	 
	5.04 Patent Search
	 	 	21	 
	 
	 	 	 	 
	5.05 Solving of Disputes
	 	 	22	 
	 
	 	 	 	 
	Article VI. Funding of Development Work
	 	 	22	 
	 
	 	 	 	 
	6.01 Payment Schedule
	 	 	22	 
	 
	 	 	 	 
	6.02 Payment Schedule, Invoices
	 	 	23	 
	 
	 	 	 	 
	6.03 Overdue payments
	 	 	23	 
	 
	 	 	 	 
	6.04 No Setoff
	 	 	24	 
	 
	 	 	 	 
	6.05 Expenses
	 	 	24	 
	 
	 	 	 	 
	Article VII. Commercialization
	 	 	24	 
	 
	 	 	 	 
	Article VIII. License Grants
	 	 	24	 
	 
	 	 	 	 
	8.01 NuPathe Grants
	 	 	24	 
	 
	 	 	 	 
	8.02 LTS Grants
	 	 	25	 
	 
	 	 	 	 
	8.03 Specific LTS Manufacturing Know How
	 	 	25	 
	 
	 	 	 	 
	Article IX. Inventions and Data
	 	 	26	 
	 
	 	 	 	 
	9.01 Inventions
	 	 	26	 
	 
	 	 	 	 
	9.02 NuPathe Inventions
	 	 	26	 
	 
	 	 	 	 
	9.03 LTS Inventions
	 	 	27	 
	 
	 	 	 	 
	9.04 Joint Inventions
	 	 	27	 
	 
	 	 	 	 
	9.05 Transfer
	 	 	30	 
	 
	 	 	 	 
	9.06 Use of Inventions
	 	 	30	 
	 
	 	 	 	 
	9.07 Data
	 	 	30	 
	 
	 	 	 	 
	Article X. Confidentiality
	 	 	31	 
	 
	 	 	 	 
	Article XI. Patent Infringements
	 	 	31	 
	 
	 	 	 	 
	11.01 Notices
	 	 	31	 
	 
	 	 	 	 
	11.02 Joint Patents
	 	 	32	 
	 
	 	 	 	 
	11.03 Literature Research on Patents
	 	 	33	 
	 
	 	 	 	 
	11.04 No Warranty
	 	 	33	 
	 
	 	 	 	 
	11.05 Patent Infringement
	 	 	34	 

4

 

TABLE OF CONTENTS

(continued)

	 	 	 	 	 
	 	 	Page	 
	11.06 Assistance
	 	 	34	 
	 
	 	 	 	 
	Article XII. Liability and Indemnification
	 	 	35	 
	 
	 	 	 	 
	12.01 No warranty
	 	 	35	 
	 
	 	 	 	 
	12.02 Product Liability
	 	 	35	 
	 
	 	 	 	 
	12.03 Burden of proof
	 	 	37	 
	 
	 	 	 	 
	12.04 Insurance
	 	 	37	 
	 
	 	 	 	 
	Article XIII. Term and Termination
	 	 	37	 
	 
	 	 	 	 
	13.01 Term
	 	 	37	 
	 
	 	 	 	 
	13.02 Termination by either Party
	 	 	37	 
	 
	 	 	 	 
	13.03 Termination by NuPathe
	 	 	37	 
	 
	 	 	 	 
	13.04 Termination for Default
	 	 	38	 
	 
	 	 	 	 
	13.05 Termination by Either Party
	 	 	38	 
	 
	 	 	 	 
	13.06 Surviving Rights
	 	 	38	 
	 
	 	 	 	 
	13.07 Effect of Termination
	 	 	38	 
	 
	 	 	 	 
	Article XIV. Miscellaneous Provisions
	 	 	39	 
	 
	 	 	 	 
	14.01 No Guarantee
	 	 	39	 
	 
	 	 	 	 
	14.02 No Agency
	 	 	39	 
	 
	 	 	 	 
	14.03 No License
	 	 	39	 
	 
	 	 	 	 
	14.04 Force Majeure
	 	 	40	 
	 
	 	 	 	 
	14.05 No Indirect, Punitive or Exemplary Damages
	 	 	40	 
	 
	 	 	 	 
	14.06 Settlement of Disputes
	 	 	41	 
	 
	 	 	 	 
	14.07 Choice of Law and Jurisdiction
	 	 	41	 
	 
	 	 	 	 
	14.08 No Jury Trial
	 	 	41	 
	 
	 	 	 	 
	14.09 Notices
	 	 	42	 
	 
	 	 	 	 
	14.10 Official Language
	 	 	42	 
	 
	 	 	 	 
	14.11 Severability
	 	 	42	 
	 
	 	 	 	 
	14.12 Titles
	 	 	43	 
	 
	 	 	 	 
	14.13 Amendment
	 	 	43	 
	 
	 	 	 	 
	14.14 Entire Agreement
	 	 	43	 

ANNEX A Active Principle Specifications

ANNEX B Development Plan

ANNEX C LTS Outlines of Principles for Manufacturing Agreements

ANNEX D Specifications

ANNEX E Active Principle Data

ANNEX F Investment Costs for manufacture of clinical samples

ANNEX G LTS Product Liability Insurance

ANNEX H Quality Agreement

5

 

DEVELOPMENT AND LICENSE AGREEMENT

THIS AGREEMENT, effective as of September 14, 2007 (“Effective Date”) by and among LTS Lohmann
Therapie-Systeme AG, a company organized under the laws of Germany having a principal place of
business at Lohmannstraße 2, 56626 Andernach, Federal Republic of Germany (“LTS”);

AND

NuPathe Inc., a corporation organized under the laws of Delaware having a principal place of
business at 375 East Elm Street, Suit 110, Conshohocken, PA 19428, USA (“NuPathe”)

WITNESSETH

     WHEREAS, NuPathe is engaged in the research and development of new products including Active
Principle and Active Principle compositions for use in the health care field.

     WHEREAS, NuPathe has acquired rights to an iontophoretic transdermal technology for the use
with the Active Principle.

     WHEREAS, LTS is engaged and experienced in developing and manufacturing transdermal
therapeutic systems for the delivery of pharmaceutical ingredients through the skin (“TTS”).

     WHEREAS, NuPathe is interested in a cooperation concerning Product.

     WHEREAS, the parties intend to collaborate in the commercialization of such Product resulting
from the development work under this agreement, during which, subject, however to the terms and
conditions of this agreement NuPathe would market, distribute, sell and/or have marketed,
distributed or sold such Product and LTS would exclusively manufacture and supply NuPathe’s
requirements therefore.

     NOW THEREFORE, in consideration of the premises and mutual covenants and conditions set forth
herein, the Parties agree as follows:

6

 

Article I. Definitions

	1.01	 	Introduction
	 
	 	 	When used in this Agreement, each of the following terms shall have the meanings set out in
this Article I.
	 
	1.02	 	“Active Principle”
	 
	 	 	shall mean the active pharmaceutical ingredient Sumatriptan Succinate ready to be used for
the development of the Product (as hereinafter defined) and for the manufacturing of
Clinical Samples (as hereinafter defined) and the Product.
	 
	1.03	 	“Active Principle Specifications”

means the specifications of the Active Principle, set forth in Annex A.
	 
	1.04	 	“Affiliate”
	 
	 	 	means any person or business entity which directly or indirectly controls, is controlled by,
or is under common control with a Party to this Agreement. A business entity shall be deemed
to “control” another business entity, if it owns directly or indirectly, more than fifty
percent (50%) of the outstanding voting securities, capital stock, or other comparable
equity or ownership interest of such business entity, or exercises equivalent influence over
such entity. If the laws of the jurisdiction in which such entity operates prohibit
ownership by a Party of more than fifty percent (50%), “control” shall be deemed to exist at
the maximum level of ownership allowed by such jurisdiction.
	 
	1.05	 	“Agreement”
	 
	 	 	shall mean this agreement and the annexes thereto.

7

 

	1.06	 	“Annex”
	 
	 	 	means an exhibit to this Agreement which sets out details of the Agreement and shall be
binding only if signed by legal representatives of the parties.
	 
	1.07	 	“cGMP”
	 
	 	 	means current good manufacturing practices, as applicable, as described in (i) Parts 210,
211 and 820 of Title 21 of the United States’ Code of Federal Regulations, (ii) Division 2
of Part C of the Food and Drug Regulations (Canada), (iii) EC Directive 91/356/EEC and (iv)
the latest Health Canada, FDA and European Medicine Evaluation Agency guidance documents
pertaining to manufacturing and quality control practice, as updated, amended and revised
from time to time and as applicable under the particular circumstances.
	 
	1.08	 	“Clinical Samples”
	 
	 	 	mean samples of the Product complying with the Specifications manufactured by LTS according
to cGMP and the Quality Agreement and supplied to NuPathe for purposes of evaluation by
NuPathe in one or more clinical studies.
	 
	1.09	 	“Commercially Reasonable Efforts”
	 
	 	 	means those efforts employed by the Parties, equivalent to that level of attention and care
that they devote to their other businesses and products of similar commercial potential and
at a similar stage of progress of development.
	 
	1.10	 	“Defective”
	 
	 	 	means in connection with the term “Product” or “Clinical Samples” any Product or Clinical
Samples which does not meet the Specifications and / or is not manufactured

8

 

	 	 	according to cGMP and according to applicable laws and regulations. Defect shall be
construed accordingly.
	 
	1.11	 	“Development Committee”
	 
	 	 	means a group composed of one or more representative(s) from NuPathe and representatives
from LTS, which shall be responsible for planning and monitoring the Project to ensure
diligent completion thereof.
	 
	1.12	 	“Development Work”

means the activities set forth in the Development Plan, attached hereto.
	 
	1.13	 	“Development Plan”
	 
	 	 	means the plan attached hereto as Annex B, which sets forth the activities to be performed
and the timelines for such activities. The Development Plan may be amended by the mutual
written agreement of the parties.
	 
	1.14	 	“FDA”
	 
	 	 	means the United States Food and Drug Administration and any successor agency thereto.
	 
	1.15	 	“Iontophoretic Components”
	 
	 	 	means all materials related to the iontophoretic operation of the Product, including but not
limited to assembled iontophoretic circuits, power sources, electrodes, batteries, and other
components necessary for operation of the Product.

9

 

	1.16	 	“LTS Know How”
	 
	 	 	means proprietary information of LTS regarding the general development and manufacture of
TTS and related technologies.
	 
	1.17	 	“LTS Intellectual Property”
	 
	 	 	means all right, title and interest to LTS Know-How, including but not limited to LTS’
Patents.
	 
	1.18	 	“LTS Patents”
	 
	 	 	means any patent or application owned or controlled by LTS covering general development and
manufacture of TTS and related technologies
	 
	1.19	 	“Major Market Country”
	 
	 	 	shall mean the United States and each country of the European Union.
	 
	1.20	 	“Manufacturing Agreement”
	 
	 	 	shall mean the manufacturing and supply agreement to be concluded between the Parties for
the commercial manufacture and supply of the Product consistent with LTS’ Outlines of
Principles for Manufacturing Agreements, which are attached hereto as Annex C.
	 
	1.21	 	“NuPathe Know How”
	 
	 	 	means proprietary information of NuPathe concerning iontophoresis, the Iontophoretic
Components, the Active Principle.
	 
	1.22	 	“NuPathe Intellectual Property”
	 
	 	 	means all right, title and interest in and to all proprietary information of NuPathe
regarding the SmartReliefTM iontophoretic patch technology including, without

10

 

	 	 	limitation, design, specifications, engineering, drug formulation and technology, including
Patents related thereto and NuPathe Know-How.
	 
	1.23	 	“Patents”
	 
	 	 	shall mean any patents or patent applications and any continuations, continuations-in-part,
divisions, provisionals, substitutions, patents of addition, reissues, reexamination,
renewals or extensions thereof (including any supplemental patent certificates) and any
confirmation patent or registration patent and all foreign counterparts of any of the
foregoing.
	 
	1.24	 	“Product”
	 
	 	 	means a TTS containing Active Principle, combined with the Iontophoretic Components.
	 
	1.25	 	“Party”

shall mean a Party to this Agreement.
	 
	1.26	 	“Project”
	 
	 	 	means collaboration of the Parties under this Agreement with the objective to develop and
commercialize the Product.
	 
	1.27	 	“Quality Agreement”
	 
	 	 	means the Quality Agreement attached hereto as Annex___and executed simultaneously with this
Agreement
	 
	1.28	 	“Report”
	 
	 	 	means the final report to NuPathe containing LTS’s results of LTS’ activities under this
agreement to develop a Product.

11

 

	1.29	 	“Specifications”
	 
	 	 	means the written specifications developed in accordance with the Quality Agreement for the
manufacturing and quality control of the Product, and any and all additions and amendments
to the same made by the written agreement of the Parties during the term of this Agreement.
	 
	 	 	The Specifications will be attached to and made a part of this Agreement as Annex D.
	 
	1.30	 	“Sublicensee”
	 
	 	 	means a Party whom NuPathe has sublicensed its license(s) granted hereunder in accordance
with Section 4.03 subsection (b) of this agreement.
	 
	1.31	 	“Territory”
	 
	 	 	means worldwide.
	 
	1.32	 	Interpretation
	 
	 	 	Unless the context of this Agreement requires otherwise,

	 	(i)	 	words of any gender include each other gender,
	 
	 	(ii)	 	words using the singular or plural number also include the plural or singular
number, respectively,
	 
	 	(iii)	 	the terms “hereof”, “herein”, “hereunder”, “hereby” and derivative or similar
words refer to this entire Agreement,
	 
	 	(iv)	 	the terms “Article” or “Section” refer to the specified Article or Section of
this Agreement, and

12

 

Article II. Contribution of LTS

	2.01	 	LTS Contribution.
	 
	 	 	LTS shall use its Commercially Reasonable Efforts to perform the Development Work and to
perform the Development Work in accordance with the Quality agreement and all applicable
laws and regulations, including standards of cGMP.
	 
	2.02	 	Report.
	 
	 	 	The Development Work shall culminate in a Report summarizing and documenting the Development
Work.
	 
	 	 	LTS shall use Commercially Reasonable Efforts to present the Report to NuPathe within sixty
(60) days after completion of the Development Work.
	 
	 	 	NuPathe may request reasonable modifications to such Report within thirty (30) days after
receiving the Report and LTS shall make such reasonable modifications within thirty (30)
days after receipt of NuPathe’s written request. In the event NuPathe does not comment on
the draft within such thirty (30) days period, then the Report shall be deemed accepted.
	 
	2.03	 	Clinical Samples.
	 
	 	 	LTS shall use its Commercially Reasonable Efforts to manufacture and supply to NuPathe
Clinical Samples. It is being understood that NuPathe shall pay no other compensation for
the delivery of Clinical Samples, other than the compensation as provided for in Article VI.

13

 

	2.04	 	Timelines.
	 
	 	 	LTS shall use its Commercially Reasonable Efforts to perform the Development Work within the
timelines set forth in the Development Plan, however NuPathe acknowledges that due to the
developmental nature of such work LTS is unable to warrant or guarantee the completion of
the Project within those time limits. In the event LTS becomes aware that it will not be
able to comply with the timelines set forth in the Development Plan, it shall inform NuPathe
in due time.
	 
	2.05	 	Implementation of the Project.
	 
	 	 	LTS shall have sole control over the implementation of the LTS activities as established by
the decisions and recommendations of the Development Committee and / or the Development
Plan.
	 
	2.06	 	LTS’ Support of Registration.
	 
	 	 	LTS shall provide to NuPathe in a timely manner the information which concerns the design
and manufacture of the Product necessary for preparing the applicable regulatory documents
for NuPathe’s regulatory filings and shall use its Commercially Reasonable Efforts to
provide NuPathe support reasonably required for such filing for one Major Market Country.
Subject to regulatory requirements, in the event that this requires disclosure of LTS
Know-How or confidential information of LTS customers, LTS shall have the right to
communicate such information directly to the health authorities, without disclosing same to
NuPathe. All INDs, NDAs and other regulatory filings made or filed by NuPathe with respect
to any Products shall be in the name of, and be owned solely by NuPathe.

14

 

	 	 	In the event NuPathe wishes additional support from LTS for the registration in other
countries, any activities shall be subject to the terms and conditions of this agreement,
provided, however, that such support from LTS shall be subject to a written agreement
including LTS’ compensation and the timelines for such support.
	 
	2.07	 	Audit at LTS.
	 
	 	 	In addition to any audit and/or inspection rights set forth in the Quality Agreement, LTS
will permit an authorized representative of NuPathe or its Affiliates to inspect at all
reasonable times the process of manufacture and storage of the Clinical Samples under such
conditions as LTS may reasonably require in order to protect the confidentiality of its and
its other customer’s proprietary and confidential information.
	 
	2.08	 	Establishment Registration/Device Listing
	 
	 	 	If necessary, LTS shall use its Commercial Reasonable Efforts to file a Registration of
Device Establishment and Medical Device Listing pursuant to 21 CFR 807. NuPathe shall pay
all costs related thereto.

Article III. Contributions of NuPathe

	3.01	 	NuPathe Cooperation.
	 
	 	 	NuPathe shall use its Commercially Reasonable Efforts to duly cooperate during the entire
course of the Project.
	 
	3.02	 	Active Principle Supply.
	 
	 	 	NuPathe shall supply LTS with such quantities of Active Principle at such times as LTS reasonably,
at its discretion, needs for the Project [**] and will ship the Active Principle DDP (Incoterms
2000). All Active Principle supplied hereunder shall be utilized by LTS

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND
WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL
TREATMENT REQUEST.

15

 

	 	 	solely for conducting work on the Project and any unused quantities shall be returned
to NuPathe at NuPathe’s cost.

	 	(1)	 	NuPathe’s Compliance with Active Principle Specifications. NuPathe
represents and warrants that Active Principle delivered under this Agreement conforms
to the Active Principle Specifications as the Parties have agreed upon and has been
manufactured according to cGMP and all other applicable statutes, laws and regulations.
LTS shall check for identity only all such supplies within ten (10) days of receipt
thereof.
	 
	 	(2)	 	Audit at Supplier of Active Principle. If it is required by law,
NuPathe shall enable authorized representative of LTS or its Affiliates upon written
reasonable advance notice to inspect at all reasonable times the process of manufacture
and storage of the Active Principle supplies, under such conditions as NuPathe or any
supplier of the Active Principle may reasonably require in order to protect the
confidentiality of its and its other customer’s proprietary and confidential
information.

	3.03	 	Active Principle Data.
	 
	 	 	NuPathe shall supply LTS with relevant data related to the Active Principle including safety
data sheet and all other information LTS might additionally require in pursuance of the
Project.
	 
	3.04	 	Evaluating Results.
	 
	 	 	NuPathe shall duly evaluate the results in any
interim report and the Report in order to promote
the Project as much as practical.

16

 

	3.05	 	Iontophoresis Components
	 
	 	 	NuPathe shall supply LTS with sufficient quantities of Iontophoretic Components, as LTS
reasonably requires for the Project [**]. All Iontophoretic Components supplied hereunder
shall conform to the Specifications and shall be utilized by LTS solely for conducting work
on the Project.
	 
	3.06	 	Clinical Trials.
	 
	 	 	NuPathe shall be responsible for planning and carrying out all clinical trials of Products.
NuPathe shall perform such clinical trials in accordance with all applicable laws and
regulations.
	 
	3.07	 	Registration of Products.
	 
	 	 	NuPathe shall be responsible for preparing in a timely manner the applicable regulatory
documents and filing for registration and approval of Products in the Territory. Any
sections of the filing for registration relevant for LTS shall be subject to LTS’ prior
approval which shall not be unreasonably withheld.
	 
	3.08	 	Upgrade to the LTS’ facility
	 
	 	 	NuPathe shall reimburse LTS for investment costs specified in Annex F and all other
investment costs which are directly related to specific tools and equipment necessary for
manufacturing the clinical samples of Product, which are currently not available for the
manufacture of the clinical samples of Product at LTS.

	 	(a)	 	NuPathe shall pay the costs within thirty (30) days of submission by LTS to
NuPathe of the respective invoice. LTS may invoice NuPathe, once it has entered into a
firm commitment to purchase tools or equipment. LTS will fulfill its

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

17

 

	 	 	 	obligation to pay the third party vendor(s). NuPathe shall have the right to audit
invoices received by LTS for the purchase of such equipment and/or tools in LTS’
rooms in Andernach, Germany at a time mutually convenient to both parties.
	 
	 	(b)	 	LTS does not guarantee or assumes any liability that such specific tools and
equipment are suitable for manufacture of commercial quantities; however LTS shall use
its Commercially Reasonable Efforts to make such equipment useable for the commercial
manufacture of the Product.

Article IV. Involvement of Third Parties

	4.01	 	Involvement of Third Parties — General.
	 
	 	 	Except as set forth herein, this Agreement and the licenses granted are personal to the
Parties and cannot be assigned by a Party without the prior written authorization of the
other Party, such authorization not to be unreasonably withheld. Such an authorization shall
not be required for assignments by a Party to one of its Affiliates or in connection with
the transfer or sale of all or substantially all of its assets, stock or business or its
merger, consolidation or combination with or into another entity, provided however, that
this exception does not apply in case of NuPathe assignment to an entity who’s primary
business is the manufacturing of transdermal patches. Subject to the foregoing, this
Agreement shall be binding upon, inure to the benefit of and be enforceable by the
respective heirs, administrators, successors and permitted assigns of the parties.
	 
	4.02	 	Involvement of Third Parties by LTS.
	 
	 	 	LTS may have certain of its tasks or duties performed by one of its Affiliates, or, after
written authorization of NuPathe, which shall not be withheld unreasonably, by a third

18 

 

	 	 	party under obligation of confidentiality, if same is necessary for the timely performance
of the Development Work, however, LTS shall remain solely responsible for the performance of
the Development Work in accordance with the terms hereof. If LTS chooses to have certain of
its tasks or duties performed by one of its Affiliates or a third party according to the
foregoing or if the Parties determine that the Product shall be manufactured in the
facilities of LTS’ Affiliates, then all licenses in favor of LTS hereunder shall be deemed
to be granted to such LTS’ Affiliate or such third party for the period during which it is
performing LTS’ tasks or duties or is manufacturing the Product and such Affiliates or third
parties shall:

	 	(a)	 	assume the obligations to indemnify NuPathe according to this Agreement and the
Manufacturing Agreement; and
	 
	 	(b)	 	provide a sufficient product liability insurance coverage equal to the
coverage, which LTS is obliged to provide according to this Agreement and the
Manufacturing Agreement.

	4.03	 	Involvement of Third Parties by NuPathe.
	 
	 	 	The grant of licenses to NuPathe by LTS may be sublicensed by NuPathe to those of NuPathe’s
third party sublicensees that require such license rights for the use, sale, importation,
distribution or marketing of the Products, provided, that.

	 	(a)	 	LTS is informed of the identity of the potential sublicense and the scope of
rights that are being granted;

19 

 

	 	(b)	 	those sublicensees additionally assume the obligations to indemnify LTS
according to this Agreement and the Manufacturing Agreement; and
	 
	 	(c)	 	those sublicensees provide a sufficient product liability insurance coverage
equal to the coverage, which NuPathe is obliged to provide according to this Agreement
and the Manufacturing Agreement.

Article V. Development Committee

	5.01	 	Development Committee.
	 
	 	 	Within thirty (30) days after execution of this Agreement LTS and NuPathe will create a
Development Committee which shall be responsible for

	 	(a)	 	the control over the Project;
	 
	 	(b)	 	the review and approval of the Specifications subject to the Quality Agreement;
	 
	 	(c)	 	the co-ordination of all joint activities of the Parties under the Development
Plan;
	 
	 	(d)	 	the exchange of information between the Parties;
	 
	 	(e)	 	analysis of the intellectual property aspects of the Product;
	 
	 	(f)	 	the evaluation of new research projects relating to the Project;
	 
	 	(g)	 	modifying the Development Plan;
	 
	 	(h)	 	resolving any unexpected issues that may arise in the performance of this
Agreement.

20 

 

	 	 	LTS and NuPathe shall inform each other within thirty (30) business-days of the execution
hereof of the identities of other persons and its deputies it has designated to the
Development Committee. Each Party shall appoint at least one representative. The Parties
shall be entitled to replace such representatives from time to time. NuPathe and LTS shall
have equal voting rights in the Development Committee regardless of the number of
representatives designated by NuPathe and LTS respectively. Decision of the Development
Committee shall be made by unanimous written agreement of the Parties.
	 
	5.02	 	Control over Project.
	 
	 	 	The Development Committee shall have the primary control over the direction and the course
of the Development Work. The Development Committee shall modify the Development Plan as
appropriate.
	 
	5.03	 	Meetings.
	 
	 	 	The Development Committee shall meet at least quarterly, as appropriate also by
teleconference or videoconference, to review the progress of the Development Work, to
establish the program for the next quarter and to review if modifications to the Development
Plan and on the time schedule are required; if any
	 
	5.04	 	Patent Search.
	 
	 	 	The Development Committee shall work with competent patent counsel of both of LTS and
NuPathe to search frequently the patent literature in order to avoid that the Product
infringes any third party’s patent, or to take appropriate action if any such patent exists.
Such patent search and its results shall be reported orally to members of the Development
Committee and to the legal departments of either Party. For the avoidance of doubt, this

21 

 

	 	 	clause does not apply to patents held independently of the Project by either Party including
but not limited to patents relating to the Active Principle, NuPathe Intellectual Property,
NuPathe Know-how. LTS Intellectual Property or LTS Know-how.
	 
	5.05	 	Solving of Disputes.
	 
	 	 	If an unanimous decision cannot be reached within the Development Committee, each Party has
the right to ask for discussions of the problem on the management level. In this case the
appropriate management level of the Parties shall enter into good faith negotiations on the
problem without undue delay. If such individuals cannot resolve such dispute, then NuPathe
shall have the deciding vote; provided, however, that notwithstanding the foregoing, LTS
shall not be obligated, as a result of such a deciding vote by NuPathe, to violate any
obligation or agreement it may have with any third party and provided further that subject
to Sections 12.02 and 14.05, NuPathe shall indemnify and hold LTS harmless from such damages
resulting from such decision.

Article VI. Funding of Development Work

	6.01	 	Payment Schedule.

	 	(1)	 	NuPathe shall compensate LTS for all man—hours actually expended by LTS on the
Project according to the Development Plan for development activities, for production
testing, scale-up activities and — as applicable — to validation activities, and
registration activities at the rate of € [**],-per man-hour [**].
	 
	 	(2)	 	During the term of this Agreement, LTS may increase the man-hour rate set forth
above at the end of each calendar year (with such increase to take effect at the
beginning of the next calendar year), provided, however, that such increase shall

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

22 

 

	 	 	not exceed [**] percent ([**] %) of the man-hour rate for the previous year, or [**]
percent ([**] %) in two (2) consecutive years.
	 
	(3)	 	LTS will take reasonable steps to verify and document the time devoted by LTS’
employees to the Project, and will monthly submit an accounting to NuPathe. LTS will
allocate man-hours consistently with its historical allocation practice and will
provide NuPathe with a sufficiently detailed explanation of such practice, upon
request, so as allow an independent Certified Public Accountant or chartered accountant
appointed by NuPathe and reasonably acceptable to LTS to audit same.

	6.02	 	Payment Schedule, Invoices.
	 
	 	 	LTS may monthly send out invoices to NuPathe. NuPathe shall make all payments within thirty
(30) days of date of invoice by LTS, detailing value added tax separately, to a bank account
designated by LTS. A copy of the invoice shall be sent by fax parallel to mailing the
invoice; however, no payment shall be due within said thirty (30) days until an original
invoice has been received by NuPathe.
	 
	6.03	 	Overdue payments.
	 
	 	 	Overdue payments shall accrue interest at the rate of 4 (four) per cent above EURIBOR —
EURO Interbank Offered Rate (three months) — as reported in the Handelsblatt, Frankfurt on
the first business day that any payments becomes overdue, until made.
	 
	6.04	 	No Setoff.
	 
	 	 	NuPathe shall not be entitled to exercise any right of setoff, net-out or deduction, take
any credit, or assert any other defense arising out of any transaction unless and until

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

23 

 

	 	 	NuPathe has obtained a final and non-appealable judgment against LTS in the amount asserted
by NuPathe.
	 
	6.05	 	Expenses.
	 
	 	 	Each Party shall bear all of the expenses of its own participation or related to its
contribution or the performance of its obligations under this Agreement unless provided for
in this Agreement. In the event of unforeseen or extraordinary expenses the Parties shall be
entitled to request an equitable allocation.

Article VII. Commercialization

	 	 	Should the Product be successfully developed, NuPathe shall have the exclusive right to
import, market, sell or distribute or have imported, marketed, sold or distributed the
Product in the Territory and LTS shall have the exclusive right to manufacture or have
manufactured Product in the Territory. Such rights are subject to the execution of a
Manufacturing Agreement on mutually agreed terms. The Parties will meet and discuss in good
faith the Manufacturing Agreement, which shall be consistent with LTS’ Outlines as set forth
in Annex C and the terms of this Agreement.

Article VIII. License Grants

	8.01	 	NuPathe Grants.
	 
	 	 	NuPathe hereby grants to LTS a non-exclusive, royalty-free license under NuPathe
Intellectual Property and all NuPathe Know-How for the sole purpose of conducting the
Development Work, and if NuPathe elects to market a Product, such license shall include

24 

 

	 	 	the right to manufacture and supply Product to NuPathe under the Manufacturing Agreement in
the Territory.
	 
	8.02	 	LTS Grants.
	 
	 	 	LTS hereby grants to NuPathe a non-exclusive, royalty-free license in the Territory under
LTS Intellectual Property and all LTS Know How for the sole purpose of conducting the
Development Work pursuant to this Agreement and, provided that the parties cooperate in the
development of Product in connection with pre-clinical, non-clinical and clinical drug
development activities reasonably necessary to the development and submission of regulatory
data to a regulatory authority for the purpose of achieving regulatory approval for the
Product. In addition, if the Parties enter into a Manufacturing Agreement for the Product,
NuPathe shall have the exclusive, royalty free right to use, import, sell, market and
distribute or have imported, sold, marketed or distributed the Products in the Territory
under the Manufacturing Agreement.
	 
	8.03	 	Specific LTS Manufacturing Know How.

	 	(1)	 	In no case shall NuPathe be entitled to request any of LTS’ information
concerning specific manufacturing LTS Know How, unless required for patent filing,
prosecution or maintenance or regulatory registration or regulatory approval purposes.
Subject to regulatory requirements, LTS will be entitled to communicate such
information directly to regulatory authorities without disclosing it to NuPathe.

25 

 

	 	(2)	 	Nothing in this Agreement shall be construed as an obligation for LTS to
provide or transfer general know-how and/or proprietary information necessary or useful
for establishing a production of transdermal or other coating products.

Article IX. Inventions and Data

	9.01	 	Inventions.
	 
	 	 	Each party shall continue to own its existing patents, trademarks, copyrights, trade
secrets, know how and other intellectual property, without conferring any interests therein
on the other party. Without limiting the generality of the preceding sentence, NuPathe shall
retain all right, title and interest in and to NuPathe Intellectual Property and LTS shall
retain all right, title and interest to LTS Intellectual Property. In the course of the
performance of the Development Work under this Agreement, LTS and NuPathe will collaborate
in the development of the Product and such collaboration may generate inventions as such
term is defined under United States patent law (“Inventions”). Ownership of such inventions
is as set forth in Articles 9.02 through 9.04 below.
	 
	9.02	 	NuPathe Inventions.
	 
	 	 	Any Inventions that are conceived, reduced to practice or created solely by LTS or in
conjunction with NuPathe as a result of LTS’ performance of the Development Work under this
Agreement which relate solely to NuPathe Intellectual Property shall be owned by NuPathe
(“NuPathe Inventions”). NuPathe may file patent applications for such Inventions at its
cost. Any compensation to an inventor under provisions of labor law shall be paid by the
employer of that inventor.

26 

 

	 	 	LTS hereby assigns to NuPathe without further compensation, all of LTS’ right with respect
to NuPathe Inventions. To ensure NuPathe’s ownership of such Inventions, LTS shall promptly
disclose each such Invention to NuPathe (or any persons designated by it), and without
disclosing the same to others, communicate to NuPathe all available information relating to
such Inventions.
	 
	9.03	 	LTS Inventions.
	 
	 	 	Any Inventions that are conceived, reduced to practice or created solely by LTS or in
conjunction with NuPathe as a result of LTS’ performance of the Development work under this
Agreement which relate solely to LTS Intellectual Property shall be owned by LTS (“LTS
Inventions”). LTS may file patent applications for such Inventions at its cost. Any
compensation to an inventor under provisions of labor law shall be paid by the employer of
that inventor.
	 
	 	 	NuPathe hereby assigns to LTS without further compensation, all of NuPathe’s rights with
respect to LTS Inventions. To ensure LTS’ ownership of such Inventions, NuPathe shall
promptly: disclose each such Invention to LTS (or any persons designated by it), and without
disclosing the same to others, communicate to LTS all available information relating to such
Inventions.
	 
	9.04	 	Joint Inventions.

	 	(1)	 	Any Inventions that are conceived, reduced to practice or created under this
Agreement that are not NuPathe Inventions or LTS Inventions shall be jointly owned by
the Parties (‘Joint Inventions”).

27 

 

	 	(2)	 	Each of LTS and NuPathe will promptly disclose to the other in writing any
Invention that might, under the applicable patent laws, be patentable and constitute a
Joint Invention that would be owned by, or jointly owned with, the other party pursuant
to this Section 9.03.
	 
	 	 	 	With respect to all patent applications (including amendments, continuations or
continuations in part) related to Joint Inventions (the “Joint Patent
Applications”), the Parties shall determine which Party shall be responsible for
filing, prosecuting, maintaining and defending patent applications and patents on
behalf of both Parties (the “Responsible Party”) based on a good faith determination
of the relative contributions of the Parties to the invention and the relative level
of interest of the Parties in the Invention.
	 
	 	 	 	At least twenty (20) days prior to the contemplated filing of such patent
application, the Responsible Party shall submit a substantially completed draft of
the Joint Patent Applications to the other Party and provide such Party with a
reasonable opportunity to review and comment on any such documents prior to filing.
	 
	 	 	 	The Responsible Party shall also promptly provide the other Party with copies of any
substantive prosecution correspondence received directly or indirectly from a patent
office or from local patent counsel assisting with patent prosecution of such
applications and the other Party shall have an opportunity to review and comment on
any response thereto. The Responsible Party will consider in good faith the other
Party’s comments and suggestions with respect to Joint Patent Applications

28 

 

	 	 	 	and/or substantive prosecution correspondence and shall use its Commercially
Reasonable Efforts to prepare, file, prosecute and maintain Joint Patents, in the
Territory that provide the broadest possible coverage for the Product and shall not
take any actions that would lessen or minimize coverage without the other Party’s
prior written approval.
	 
	 	(3)	 	Any Joint Patent Applications shall be filed and registered in the name of LTS
and NuPathe. Except as set forth below, the Parties shall share equally the costs of
the preparation, filing, prosecution and maintenance of all Joint Patent Applications.
	 
	 	(4)	 	If the Responsible Party does not wish to file, prosecute or maintain any Joint
Patent Application or maintain or defend such a patent in a particular country, it
shall grant the other Party any necessary authority to file, prosecute and maintain
such a patent application or maintain or defend such a patent in the name of both
Parties.
	 
	 	(5)	 	If either Party elects not to pay its portion of any shared costs for a Joint
Patent Application or patent issuing therefrom, the other Party may proceed with such
Joint Patent Application in its own name and at its sole expense, in which case the
Party electing not to pay its share of costs shall assign its entire right, title and
interest in and to such Joint Patent Application to the other Party and such invention
shall be treated as a sole Invention of the assignee.
	 
	 	 	 	Once a patent or other intellectual property rights are granted resulting from a
Joint Patent Application, such patent shall be defined as a “Joint Patent Right”.

29 

 

	9.05	 	Transfer.
	 
	 	 	Either Party shall have the right to license Joint Inventions to a third party , provided,
however, in the event LTS exclusively manufactures the Product on behalf of NuPathe using a
Joint Invention, LTS may not grant any license to such Joint Invention to any third party
for use in connection with the manufacture, sale, marketing, importation or distribution of
any iontophoretic patch containing sumatriptan succinate.
	 
	9.06	 	Use of Inventions.

	 	(1)	 	NuPathe shall have the right to use LTS Inventions consistent with its
contractual rights and obligations set forth in this Agreement, including those set
forth Section 8.02 hereof, or the Manufacturing Agreement for the purpose of
commercializing the Product.
	 
	 	 	 	LTS shall have the right to use NuPathe Inventions consistent with its contractual
rights and obligations set forth in this Agreement, including those set forth in
Section 8.01 hereof, or the Manufacturing Agreement.
	 
	 	(2)	 	Each Party may license patents that it owns and/or sublicense its license to
the other party’s patents as explicitly granted hereunder to any sublicensee and/or
Affiliates consistent with this Agreement or the Manufacturing Agreement, provided that
such sublicensee or Affiliate additionally assumes the rights and obligations of such
party.

	9.07	 	Data
	 
	 	 	NuPathe will own all data, information and results and technical, chemical, safety and
scientific data and information obtained or generated in connection with clinical trials of

30 

 

	 	 	the Product and non- clinical testing of the Product . Ownership of all other data and
information generated in the course of the collaboration shall be determined according to
the principles for Inventions as set forth in Sections 9.02 to 9.04.

Article X. Confidentiality

	 	 	The information of the parties generated or exchanged during the performance of activities
under this Agreement shall be treated in accordance with the terms of the Confidentiality
Agreement concluded between NuPathe Inc. and LTS Lohmann Therapy Systems Corp. dated May
31st, 2006; provided, however, that with respect to information generated or
exchanged in connection with the performance of this Agreement, all rights and obligations
of the parties with respect to nondisclosure and non use of Confidential Information shall
survive for a period of five (5) years from the expiration or termination of this Agreement.

	 	 	For purposes of clarity, each party’s intellectual property as defined herein shall be
deemed to be Confidential Information of the party owning such intellectual property. Any
disclosure of information by one party to the other under the provisions of Article X of
this Agreement shall be treated as the disclosing party’s Confidential Information under the
Confidentiality Agreement.

Article XI. Patent Infringements

	11.01	 	Notices.

	 	 	LTS and NuPathe shall each promptly
notify the other upon learning of any
infringement of any Patents covering
NuPathe Inventions, LTS Inventions or
Joint Inventions.

31

 

	11.02	 	Joint Patents.

	 	(1)	 	In the event that a patent resulting from a Joint Patent Application should be
the subject of a re-examination, interference or challenge before any court, the
Parties shall jointly defend such action. Either Party may abandon such action, by
conveying its interest in such patent to the other Party at no additional cost, in
which case the license provided for in Section 8.01 and 8.02 shall not apply to such
patent.
	 
	 	(2)	 	In the event that a Party becomes aware of any infringement or possible
infringement of any Joint Patent Rights, such Party shall promptly notify the other
Party in writing regarding such infringing activity.
	 
	 	 	 	Each Party shall have the right and authority, but not the obligation, to bring or
defend an action involving claims or counterclaims for such infringing activity on
its own upon at least thirty (30) days advance written notice to the other Party.
	 
	 	 	 	However, if both Parties wish to participate in such action, the action shall be
brought jointly by both Parties. Any action in which the Parties participate jointly
shall be jointly controlled and each Party shall bear its own expenses and be
entitled to any recoveries gained for its own damages; all other recoveries shall be
[**]. Both Parties shall have a duty to cooperate reasonably with each other with
regard to a joint action.
	 
	 	(3)	 	In the event one Party chooses not to participate jointly in an action or
similar legal recourse involving Joint Patent Rights, the other Party (the “Acting
Party”) may do so at its own expense in its own name. Any recoveries gained by the

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

32

 

	 	 	 	Acting Party in such action or similar legal recourse shall first be used to
reimburse each Party for all costs and expenses incurred in connection with pursuing
the action and then Acting Party shall keep those recoveries gained for its own
damages. The remainder, if any, shall be [**].
	 
	 	(4)	 	Upon request of the Acting Party and at the expense of the Acting Party, the
other Party (“Non-Acting Party”) shall have a duty to cooperate reasonably with the
Acting Party in any action involving Joint Patent Rights that is brought by the Acting
Party. The Acting Party shall provide the Non-Acting Party with the opportunity to
comment and keep the Non-Acting Party informed of all developments in the action.
	 
	 	(5)	 	Neither Party shall settle any action or similar legal recourse involving Joint
Patent Rights without the prior written consent of the other Party, including but not
limited to the grant of a license to a third party during any action.

	11.03	 	Literature Research on Patents.

	 	 	As set forth in Section 5.01, the Parties agree that the Development Committee, working in
conjunction with competent patent counsel of LTS and/or NuPathe, shall cooperate in order to
analyze all intellectual property aspects of the Product.

	11.04	 	No Warranty.

	 	 	LTS and NuPathe make no representation or warranty that any application for any patent is or
will be sufficient for the issuance of a patent, nor that the manufacture or use of Product
or Active Principle does not infringe any patent owned by a third party.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

33

 

	11.05	 	Patent Infringement.

	 	 	In the event of a suit against one or more Parties for patent infringement relating to the
Product relating to [**], the Parties shall share the out-of-pocket expenses resulting from
such situation (such out-of-pocket expenses shall be considered to include royalties and
damages, as well as legal expenses and settlement payments) in the ratio of [**] % for
NuPathe and [**] % for LTS, except that LTS share of such costs shall not exceed [**] % of
the payments made by NuPathe during the preceding 12 months period, and that such sharing
shall be the sole extent of their responsibility to each another in connection with such
suit, claim or license. NuPathe shall [**], for which LTS [**].

	11.06	 	Assistance.

	 	 	The Parties shall assist each other with information, evidence, and fact witnesses as may be
reasonably requested in the defense of or negotiations related to claims made against either
one of the Parties.

Article XII. Liability and Indemnification

	12.01	 	No warranty.

	 	 	LTS does not make and shall not be deemed to make any representation or warranty, express or
implied, as to the infringement of any third party’s rights to such intellectual property,
including but not limited to, patents relating to the system, patentability, quality,
merchantability, fitness for a particular use or performance of any licensed Product or that
a party will successfully design (and develop a commercially marketable licensed Product).

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

34

 

	12.02	 	Product Liability.

	 	 	LTS will [**].

	 	 	In addition LTS shall hold NuPathe harmless within the scope and to the extent of [**] from
any claim, cost, expense and damage arising out of [**] supplied by LTS to NuPathe for
clinical trials to the extent that:

	 	(a)	 	[**];
	 
	 	(b)	 	the afore-mentioned claim, expense, damage or injury is not [**].
	 
	 	 	 	NuPathe shall bear [**] and shall be [**] from any damage, claims, costs and
expenses (including reasonable attorney’s fees) arising out of [**], for which LTS
is according to the foregoing [**], including but not limited to [**].
	 
	 	 	 	The restrictions on LTS’ liability and NuPathe’s obligation to indemnify shall not
apply in the event of LTS’ willful misconduct.
	 
	 	 	 	LTS shall use [**] to maintain product liability insurance coverage of an amount
substantially similar to its product liability insurance coverage set forth in Annex
C. A certificate of LTS’ current product liability insurance is attached hereto as
Annex G.
	 
	 	 	 	The parties acknowledge that [**]. In the latter case the parties agree to discuss
in good faith the bearing of [**].

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

35

 

	12.03	 	Burden of proof.

	 	 	NuPathe shall have the burden of proof in the event NuPathe makes any claims on negligence
and/or willful misconduct.

	12.04	 	Insurance

	 	 	NuPathe shall maintain sufficient clinical trial insurance coverage of an amount reasonable
and customary in the pharmaceutical industry considering the nature and extent of the
clinical trials in question for any clinical trial conducted by NuPathe with the Product.

Article XIII. Term and Termination

	13.01	 	Term.

	 	 	This Agreement shall remain in effect until terminated in accordance with Section this
Article 13, or the Manufacturing Agreement is executed by the Parties.

	13.02	 	Termination by either Party.

	 	 	If the Development Committee, in good faith, determines that it is not feasible to jointly
develop a Product either Party may terminate this Agreement on sixty (60) days
notice.
	 
	13.03	 	Termination by NuPathe.

	 	 	NuPathe shall be entitled to terminate this Agreement upon sixty (60) days written notice to
LTS thereof. In such an event, NuPathe shall reimburse LTS for all costs incurred or
irrevocably obligated by LTS prior to the date of termination; provided, however, any
installment payments made by NuPathe that are in excess of LTS’ accumulated charges shall be
returned to NuPathe.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

36

 

	13.04	 	Termination for Default.

	 	 	If either Party shall be in default of any of its material obligations under this Agreement,
the non-defaulting Party shall give the defaulting Party written notice of such default,
upon which the defaulting Party shall have sixty (60) days to cure such default or establish
that no default has occurred. In the event such default is incapable of being cured within
such sixty (60) days period, the non-defaulting party shall have the right to terminate the
agreement only, if the defaulting party did not initiate appropriate action within such
period to cure such default. In the event that a default remains uncured after sixty (60)
days have elapsed, the non-defaulting Party may declare this Agreement terminated, by
written notice to the defaulting Party.

	13.05	 	Termination by Either Party.

	 	 	If the Parties despite good faith negotiations fail to execute a Manufacturing Agreement
either Party may terminate this Agreement on thirty (30) days written notice

	13.06	 	Surviving Rights.

	 	 	Neither cancellation or termination of this Agreement nor the execution of a Manufacturing
Agreement shall relieve the Parties of their obligations of confidentiality under Article
10, their obligations as to Inventions under Article 9, their obligations regarding patent
infringements under Article 11 or their obligations regarding product liability and
indemnification under Article 12.

	13.07	 	Effect of Termination.

	 	 	Should a Party elect to terminate this Agreement pursuant to the provisions of this
Agreement, neither Party shall thereafter have any rights to the use the Intellectual

37

 

	 	 	Property, including Inventions, Patents or know-how, in so far owned by the other Party
except as provided otherwise herein.

Article XIV. Miscellaneous Provisions

	14.01	 	No Guarantee.

	 	 	EACH OF THE PARTIES ACKNOWLEDGES THAT THE WORK TO BE PERFORMED HEREUNDER IN CONNECTION WITH
THE DEVELOPMENT PROJECT IS DEVELOPMENTAL AND THAT NOTHING IN THIS AGREEMENT MAY OR SHALL BE
CONSTRUED AS A GUARANTEE OR A REPRESENTATION THAT THE PRODUCTS WILL, WITHIN A CERTAIN PERIOD
OF TIME, BE SUCCESSFULLY DEVELOPED WITH REGARD TO FITNESS FOR A PARTICULAR USE, FEASIBILITY
OF MANUFACTURING, MARKETABILITY AND ALL TECHNICAL, LEGAL AND COMMERCIAL ASPECTS RELATED
THERETO.

	14.02	 	No Agency.

	 	 	Nothing in this Agreement shall be construed as an authorization for a Party to act as an
agent for another. Furthermore, NuPathe shall incur no liability for any act or failure to
act by employees of LTS and LTS shall incur no liability for any act or failure to act by
employees of NuPathe.

	14.03	 	No License.

	 	 	Except as otherwise expressly provided herein, nothing contained in this Agreement shall be
construed or interpreted, either expressly or by implication, estoppel or otherwise, as: (i)
a grant, transfer or other conveyance by either Party to the other of any right, title,

38

 

	 	 	license or other interest of any kind in any of its Inventions or other intellectual
property, (ii) creating an obligation on the part of either Party to make any such grant,
transfer or other conveyance or (iii) requiring either party to participate with the other
Party in any cooperative development program or project of any kind or to continue with any
such program or project.

	14.04	 	Force Majeure.

	 	 	Neither Party shall be responsible or liable or shall be considered in default or liable to
the other Party for, nor shall this Agreement be terminated as a result of, any delay or
failure to perform any of its obligations hereunder, if such delay or failure results from
circumstances beyond the control of such Party, including requisition by any authority, the
effect of any statute, ordinance or governmental order or regulation, war, rebellion,
insurrection, civil commotion, riot, strike, lockout, labor disturbance, epidemic, disease,
act of God, civil commotion, explosion, fire, earthquake, storm, accident, failure of public
utilities, common carriers or suppliers or the like, or any other circumstances, whether or
not similar to the above causes and whether or not foreseeable. The Parties shall use
Commercially Reasonable Efforts to avoid or remove any such cause and shall resume
performance under this Agreement as soon as feasible whenever such cause is removed;
provided, however, that the foregoing shall not be construed to require either Party to
settle any dispute with any third party, to commence, continue or settle any litigation, or
to incur any unusual or extraordinary expense.

	14.05	 	No Indirect, Punitive or Exemplary Damages.

	 	 	Except for damages caused by or related to willful misconduct by a Party, neither Party
shall be liable to the other for any indirect, special or consequential damages, lost
profits

39

 

	 	 	and/or punitive damages, provided, that this exclusion of liability does not apply if such
agreement would be invalidated as a violation of law or public policy.

	14.06	 	Settlement of Disputes.

	 	 	The Development Committee shall attempt to amicably resolve any dispute concerning any
rights or obligations of either Party under this Agreement. If the Development Committee is
unable to resolve any such dispute, the matter shall be referred to the Chairman of the
Board of LTS and the President of NuPathe for resolution.

	14.07	 	Choice of Law and Jurisdiction.

	 	 	This Agreement shall be construed and the rights of the Parties determined in accordance
with the laws of Germany, regardless of the laws that might otherwise govern under
applicable principles of laws thereof.

	 	 	All disputes arising out of or in connection with the present agreement and any subsequent
agreement shall be finally settled under the Rules of Arbitration of the International
Chamber of Commerce by one or more arbitrators appointed in accordance with the said Rules.

	 	 	The Arbitration shall be held in Toronto, Canada or any other place that the parties may
agree upon. The arbitration shall be conducted in English. The award of arbitration shall be
final and binding upon both parties.

	14.08	 	No Jury Trial.

	 	 	In the event that any dispute or claim of any sort arising out of this Agreement or any
subsequent agreement concerning the subject matter and or any dispute or claim concerning
competent court and/or jurisdiction and/or execution of any award granted by

40

 

	 	 	a foreign court or arbitration panel should be filed, each of the Parties waives irrevocably
any right that such Party may have to demand or request a trial by jury.

	14.09	 	Notices.

	 	 	Any notice required or permitted to be given under this Agreement shall be in writing and
shall be deemed to have been sufficiently given for all purposes if mailed by first class
certified or registered mail, or commercial delivery service, postage prepaid. Unless
otherwise specified in writing, the mailing addresses of the Parties shall be as described
above.

	14.10	 	Official Language.

	 	 	This Agreement is written in the English language and English shall be the language employed
in all correspondence as well as in all communication and documentation by the Development
Committee.

	14.11	 	Severability.

	 	 	The provisions of this Agreement shall be deemed severable. Therefore, if any part of this
Agreement is rendered void, invalid or unenforceable, such rendering shall not affect the
validity or enforceability of the remainder of this Agreement and shall be replaced by
provisions that are economically similar; provided that if the part or parts which are void,
invalid or unenforceable as aforesaid shall substantially impair the value of the whole
Agreement to either Party, that Party may cancel and terminate this Agreement by giving
written notice to the other Party.

41

 

	14.12	 	Titles.

	 	 	The titles of the Articles and Sections of this Agreement are for general information and
reference only, and this Agreement shall not be construed by reference to the titles.

	14.13	 	Amendment.

	 	 	This Agreement may not be amended, supplemented or otherwise modified except by an
instrument in writing signed by both Parties.

	14.14	 	Entire Agreement.

	 	 	This Agreement, including the Appendices attached hereto, constitutes and contains the
complete, final and exclusive undertaking and agreement of LTS and NuPathe hereto, and
cancels and supersedes any and all prior negotiations, correspondence, understandings and
agreements whether oral or written, between the Parties respecting the subject matter
hereof.

     IN WITNESS WHEREOF, the Parties hereto have executed this Agreement by their respective
officers thereunto duly authorized.

	 	 	 	 	 
	 

	 	 	 	 
	LTS Lohmann Therapie-Systeme AG

	 	NuPathe Inc.	 	 
	 
	 	 	 	 
	/s/ Becher

	 	/s/ Jane H. Hollingsworth	 	 
	 

	 	 	 	 
	Name: Becher

	 	Name: Jane Hollingsworth	 	 
	Title: General Counsel

	 	Title: CEO	 	 
	Place, Date: Andernach, 12.09.2007

	 	Place, Date: Conshohocken, PA 14-09-2007	 	 
	 
	 	 	 	 
	/s/ ppa. Marc Denker

	 	/s/ Jane H. Hollingsworth	 	 
	 

	 	 	 	 
	Name: Marc Denker

	 	Name: Jane Hollingsworth	 	 
	Title: Head of Sales and Marketing

	 	Title: CEO	 	 
	Place, Date: Andernach, 12.09.2007

	 	Place, Date: Conshohocken, PA 14-09-2007	 	 

42

 

ANNEX A Active Principle Specifications

     [**]

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

43

 

ANNEX B Development Plan

     [**]

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

44

 

ANNEX C LTS Outlines of Principles for Manufacturing Agreements

	1.	 	Manufacturing. LTS shall manufacture the Product in compliance with the agreed upon
Specifications and applicable current GMP. LTS shall be deemed to have fulfilled any of its
obligations arising out of this Agreement and any subsequent agreement by employing
commercially reasonable efforts.

	2.	 	Minimum Quantities. To be negotiated.

	3.	 	Forecast. NuPathe shall supply a forecast of orders for a [**] period which shall be
updated at the beginning of [**] (Rolling Forecast).

	4.	 	Firm orders. Firm orders will be made at the latest [**] in advance of the required
delivery date, during the first year of the agreement [**] in advance.

	5.	 	Delivery Terms and Conditions. To be negotiated.

	6.	 	Exclusivity. LTS shall be the exclusive manufacturer of the Product, subject to
certain exemptions, to be determined later on.

	7.	 	Second Source.

	 	 	Upon NuPathe’s request LTS shall qualify, as far as technical possible, the manufacturing
site at LTS Lohmann Therapy Systems Corp. in West Caldwell, New Jersey, USA as a second
source of supply, provided, however, that NuPathe shall bear all costs related thereto. In
addition NuPathe shall have the right, in case LTS Corp. and LTS is not able to supply
Product to NuPathe from the Andernach Facility and the West Caldwell Facility, to have the
Product manufactured by a third party. In this event LTS shall

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

45

 

	 	 	provide such know-how and assistance, a state of the art manufacturer of transdermal
therapeutic systems would reasonably require to manufacture Product.

	8.	 	Price and Payment Terms and Conditions. To be negotiated.

	9.	 	Specific Expenses. NuPathe shall

	 	a)	 	refund LTS for specific investment costs and expenses for establishing
manufacturing related to specific equipment necessary for manufacturing the Product,
and
	 
	 	b)	 	remunerate LTS for establishing manufacturing (scaling up, validation, waste,
etc.), based on a man hour rate of € [**].

	10.	 	Replacement. LTS will replace [**].

	11.	 	LTS Liability. LTS shall assume [**].

	 	 	LTS shall maintain product liability insurance and use [**] to maintain substantially
similar coverage as the insurance coverage set forth in the certificate of insurance
provided to NuPathe.

	 	 	The parties acknowledge that [**]. In the latter case the parties agree to discuss in good
faith the bearing of [**].

	 	 	The restrictions on liability and NuPathe’s obligation to indemnify LTS shall not apply in
the event of LTS’ wilful misconduct.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

46

 

	12.	 	NuPathe Responsibility. NuPathe shall [**] for the Specifications, the availability
of components and, (after consultation with LTS) the registration. NuPathe shall [**]
mentioned in this section.

	13.	 	Use of Product and Samples. NuPathe shall [**] to itself, its employees or any third
party arising from the use of Product or samples thereof. NuPathe shall indemnify and hold LTS
harmless from [**] arising out of or related to [**].

	14.	 	Patents.

	 	a)	 	LTS shall have [**].
	 
	 	b)	 	In the event of a suit against one or more Parties for patent infringement
relating to [**], the Parties shall share the out-of-pocket expenses resulting from
such situation [**] (such out-of-pocket expenses shall be considered to include
royalties and damages, as well as legal expenses and settlement payments) in the ratio
of [**]% for NuPathe and [**]% for LTS, except that LTS share of such costs shall not
exceed [**] % of the payments made by NuPathe to LTS during the preceding 12 months and
that [**]. NuPathe shall [**].

	15.	 	No warranty. LTS does not make and shall not be deemed to make any representation or
warranty, express or implied, as to the infringement of any third party’s rights to such
intellectual property, including but not limited to, patents relating to the system,
patentability, quality, merchantability, fitness for a particular use or performance of any
licensed Product or that a party will successfully design (and develop a commercially
marketable licensed Product).

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

47

 

	16.	 	Sublicenses. NuPathe shall grant LTS and sublicensees a non-exclusive royalty-free
license with regard to any relevant own patent for the sole purpose of manufacturing. NuPathe
and LTS shall have the right to sublicense or delegate its obligations and rights to an
affiliate.

	17.	 	Term. The duration of the agreement shall be for a period of [**] from the first
launch of Product.
	 
	18.	 	Jurisdiction. Choice of law, place of venue and of
jurisdiction shall be at the place of business of LTS.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

48

 

ANNEX D Specifications

[**]

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

49

 

ANNEX E Active Principle Data

	 	 	 	 	 

	 
	 	 	Material Safety Data Sheet
	

	 	12601 Twinbrook Parkway

Rockville, MD 20852 USA
	 	Telephone calls: (301) 881-0666

8:00am — 5:00pm EST Mon. — Fri.
	 	 	Responsible Party: Reference Standards Technical Services
	 

ATTENTION!

USP Reference Standards are sold for chemical test and assay purposes only, and NOT for human
consumption. The information contained herein is applicable solely to the chemical substance when
used as a USP Reference Standard and does not necessarily relate to any other use of the substance
described, (i.e. at different concentrations, in drug dosage forms, or in bulk quantities). USP
Reference Standards are intended for use by persons having technical skill and at their own
discretion and risk. This information has been developed by USP staff from sources considered
reliable but has not been independently verified by the USP. Therefore, the USP Convention cannot
guarantee the accuracy of the information in these sources nor should the statements contained
herein be considered an official expression. NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED,
INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE is made with
respect to the information contained herein.

	 	 	 	 	 	 	 

	 
	SUMATRIPTAN SUCCINATE	 	 
	Catalog Number: 1642201

	 	Package Size: 1642201
	 	Revision Date:
	 	August 14, 2002
	 

SECTION 1 — IDENTIFICATION

	 	 	 	 	 	 	 

	Common Name:

	 	Sumatriptan Succinate
	 	Formula:
	 	C14H21N3O2S . C4H604
	Synonym:

	 	n/f	 	 	 	 
	Chemical Name:	 	1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-, butanedioate (1:1)
	CAS Number:

	 	103628-48-4
	 	RTECS
	 	EJ9940000
	 

	 	 	 	Number:	 	 
	Chemical Family:

	 	n/f	 	 	 	 
	Therapeutic

	 	Antimigraine	 	 	 	 
	Category:
	 	 	 	 	 	 

SECTION 2 — INGREDIENT INFORMATION

	 	 	 	 	 

	Principle Components
	 	Percent
	 	Exposure Limits
	 
	 	 
	 	 
	Sumatriptan Succinate
	 	Pure Material
	 	n/f

SECTION 3 — HEALTH HAZARD INFORMATION

	 	 	 

	Usual Adult Dose:

	 	The usual oral adult dose of sumatriptan succinate is 25 to 100 mg (base)
as a single dose.

50

 

	 	 	 

	Adverse Effects:

	 	Adverse effects may include severe chest pain; difficulty swallowing;
heaviness, tightness, or pressure in chest or neck; nausea or vomiting;
atypical sensations; discomfort in jaw, mouth, throat, tongue. Nasal
cavity, or sinuses; dizziness; drowsiness; flushing; lightheadedness;
muscle aches, cramps, or stiffness; weakness; anxiety; general feeling of
illness or tiredness; and vision changes. Possible allergic reaction to
material if inhaled, ingested or in contact with skin.
	Overdose Effects:

	 	n/f
	Acute:

	 	Possible eye, skin, gastrointestinal and/or respiratory tract irritation.
	Chronic:

	 	Possible hypersensitization.
	Inhalation:

	 	May cause irritation. Remove to fresh air.
	Eye:

	 	May cause irritation. Flush with copious quantities of water.

	 	 	 	 	 	 	 

	 
	SUMATRIPTAN SUCCINATE	 	 
	Catalog Number: 1642201

	 	 Package Size: 1642201
	 	Revision Date:
	 	August 14, 2002
	 

	 	 	 

	Skin:

	 	May cause irritation. Flush with copious quantities of water.
	Ingestion:

	 	May cause irritation. Flush out mouth with water.
	 
	Medical Conditions 

Aggravated by 

Exposure:

	 	Hypersensitivity to material, coronary artery disease (or predisposition to),
uncontrolled hypertension, tachycardia, history of cerebrovascular accident, or
impaired liver function.
	Cross Sensivity:

	 	n/f
	Pregnancy Comments:

	 	Some studies in rats and rabbits have shown toxic effects and
abnormalities in fetuses of animals given high doses of
sumatriptan.
	Pregnancy Category:

	 	C

SECTION 4 — FIRST AID MEASURES

	 	 	 

	General:

	 	Remove from exposure. Remove contaminated clothing. Persons
developing serious hypersensitivity (anaphylactic) reactions must
receive immediate medical attention. If person is not breathing
give artificial respiration. If breathing is difficult give
oxygen. Obtain medical attention.
	Overdose Treatment:

	 	Overdose treatment should be symptomatic and supportive and may
include the following:
	 

	 	1. To decrease absorption if material was ingested, empty the
stomach by inducing vomiting or performing gastric lavage.

2. Monitor patient for at least 10 hours or while symptoms persist.

3. For patients with chest pain or other symptoms consistent with
angina pectoris, monitor electrocardiogram for evidence of
ischemia and administer appropriate treatment. [USP DI 2002]

SECTION 5 — TOXICOLOGICAL INFORMATION

	 	 	 

	Oral Rat:

	 	LD50: >2939 mg/kg
	Oral Mouse:

	 	LD50: n/f
	Irritancy Data:

	 	n/f

51 

 

	 	 	 	 	 	 	 

	Target Organ(s):

	 	n/f	 	 	 	 
	Listed as a Carcinogen?

	 	NTP: No

Other: No
	 	IARC: No
	 	OSHA: No

SECTION 6 — FIREFIGHTING MEASURES

	 	 	 	 	 

	Flash Point:

	 	n/f
	 	Upper Flammable Limit: r
	Auto-Ignition Temperature:

	 	n/f
	 	Lower Flammable Limit: r

			
	Extinguisher Media:

	 	Water spray, dry chemical, carbon
dioxide or foam as appropriate for
surrounding fire and materials.
	Fire and Explosion Hazards:

	 	This material is assumed to be
combustible. As with all dry powders
it is advisable to ground mechanical
equipment in contact with dry
material to dissipate the potential
buildup of static electricity.
	Firefighting Procedures:

	 	As with all fires, evacuate
personnel to a safe area.
Firefighters should use
self-contained breathing equipment
and protective clothing.

	 	 	 	 	 	 	 

	 
	SUMATRIPTAN SUCCINATE	 	 
	Catalog Number: 1642201

	 	 Package Size: 1642201
	 	Revision Date:
	 	August 14, 2002
	 

SECTION 7 — PHYSICAL HAZARDS

	 	 	 

	Conditions to Avoid:

	 	Avoid exposure to light and heat.
	Incompatibilities:

	 	n/f
	Decomposition Products:

	 	When heated to decomposition material emits
toxic fumes of NOx and SOx. Emits toxic fumes
under fire conditions.
	Stable?

	 	Yes   Hazardous Polymerization? No

SECTION 8 — HANDLING / SPILL / DISPOSAL MEASURES

	 	 	 

	Handling:

	 	As a general rule, when handling USP Reference Standards avoid all contact and
inhalation of dust, mists, and/or vapors associated with the material. Wash
thoroughly after handling.
	 
	Storage:

	 	Store in tight, light-resistant container as defined in the USP-NF. This
material should be handled and stored per label instructions to ensure product
integrity. Store in a refrigerator.
	 
	Spill Response:

	 	Wear approved respiratory protection, chemically compatible gloves and
protective clothing. Wipe up spillage or collect spillage using a high
efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately
labelled container for disposal. Wash spill site.
	 
	Disposal:

	 	Dispose of waste in accordance with all applicable Federal, State and local laws.

SECTION 9 — EXPOSURE CONTROLS / PERSONAL PROTECTION

	 	 	 

	Respiratory Protection:

	 	When working with small quantities in a well-ventilated area, respiratory

52 

 

	 	 	 

	 

	 	protection may not be required. The use of an approved dust mask is recommended.
	Ventilation:

	 	No special ventilation requirements.
	Gloves:

	 	Rubber
	Eye Protection:

	 	Safety Glasses
	Protective Clothing:

	 	Protect exposed skin.

SECTION 10 — PHYSICAL AND CHEMICAL PROPERTIES

NOTE: The data reported below is general information, and is not specific to the USP
Reference Standard Lot provided!

	 	 	 	 	 

	Appearance and Odor:

	 	White to off-white powder.	 	 
	Melting Point:

	 	165 — 166° C	 	 
	Solubility in Water:

	 	Soluble
	 	Vapor Density: n/f
	Boiling Point:

	 	n/f
	 	Evaporation Rate: n/f
	Specific Gravity:

	 	n/f
	 	Reactivity in Water: n/f
	Vapor Pressure:

	 	n/f
	 	%Volatile by Volume: n/f

53

 

ANNEX F Investment Costs for manufacture of clinical samples

[**]

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

54

 

ANNEX G LTS Product Liability Insurance

Aon Jauch & Hiibener

	 	 	 
	Versicherungsbestätigung	 	Confirmation of Insurance
	Art der Versicherung

	 	Type of Cover
	 
	 	 
	Betriebs-Haftpflichtversicherung inkl.

	 	General Liability, including products liability
	Produkthaftpflicht (Grundvertrag)

	 	(Primary)
	 
	Summen-Anschlußversicherungen

	 	Excess-Layers
	 
	 	 
	Versicherungsschein Nr.

	 	Policy No.

70-5385726, 70-5563377, 70-5563378, 70-5883228

	 	 	 

	Versicherungsnehmer

	 	Named Insured

LTS Lohmann Therapie-Systeme AG

Lohmannstr. 2

56623 Andernach

	 	 	 

	Versicherungsbeginn

	 	Inception
	 
	 	 
	01.01.2007, mittags 12.00 UHR MEZ

	 	01.01.2007, at noon CET
	 
	 	 
	Versicherungsablauf

	 	Expiry
	 
	 	 
	01.01.2008, mittags 12.00 Uhr MEZ

	 	01.01.2008, at noon CET
	Der Verträge verlängern sich still-
schweigend um ein Jahr, sofern diese nicht
unter Einhaltung einer drei-
monatigen Kündigungsfrist vor dem Ab-
lauf von einem der Vertragsparteien
schriftlich gekündigt werden.

	 	The policies will be
automatically renewed for a
further year, unless one of
the contracting parties gives
written notice three months
before the date of
expiration.
	 
	 	 
	Örtlicher Geltungsbereich

	 	Policy Territory
	 
	 	 
	Weltweit

	 	Worldwide

55

 

Aon Jauch & Hiibener

	 	 	 
	Versicherungsbestätigung	 	Confirmation of Insurance
	Deckungssummen

	 	Limits of Indemnity
	 
	Personen, Sach-und mitversichte Ver-mögensschäden (pauschal) 

Je Versicherungsfall und je Versiche-rungsjahr

	 	Bodily injury, property damage and insured pure
financial loss (combined single limit) 

Any one insured event and in the annual
Aggregate

	 	 	 	 	 

	Betriebshaftpflicht

	 	EUR 10.000.000,00
	 	General Liability
	1. Anschluss

	 	EUR 40.000.000,00
	 	1. Layer
	2. Anschluss

	 	EUR 50.000.000,00
	 	2. Layer
	3. Anschluss

	 	EUR 50.000.000,00
	 	3. Layer

	 	 	 

	Es bestehen Deckungssummenbegrenz-
ungen für besondere Deckungstat-
bestände 

Bei den in den USA-Territorien und Kana-da eintretenden Versicherungsfällen oder
geltend gemachten Ansprüchen werden
die Aufwendungen des Versicherers für Kosten als
Leistungen auf die Deckungssumme angerechnet.

	 	The limits of indemnity are limited in respect
of particular types of coverage. 

In respect of insured events in or claims made
in the United States of America, its
territories and possessions and Canada costs
are within the limits.
	 
	 	 
	Rechts- und Gerichtsstand

	 	Governing Law and Jurisdiction
	 
	 	 
	Hinsichtlich der Auslegung dieser Ver-sicherungsbestätigung und des betreffen-
den Versicherungsvertrages findet aus-schließlich deutsches Recht Anwendung.
Für die aus diesem Versicherungsver hältnis
entstehenden Rechtsstreitigkeiten ist
Gerichtsstand ausschließlich der Sitz des in der
Bundesrepublik Deutschland ansässigen
Versicherungsnehmers.

	 	German law shall apply exclusively to the
interpretation of this confirmation and the
policy to which it attaches. German courts
shall have both jurisdiction and venue of any
disputes arising out of this confirmation and
the policy to which it attaches.
	 
	 	 
	Hinweis

	 	Annotation
	 
	 	 
	Ausschließlich der deutsche Versicherungsvertrag
ist rechtsverbindlich.

	 	 Only the Germany policy is legally binding.

56

 

Aon Jauch & Hiibener

	 	 	 
	Versicherungsbestätigung	 	Confirmation of Insurance
	Unabhängig von jeglicher
Voraussetzung, Bedingung oder
anderen vertraglichen
Vereinbarungen, wegen derer diese
Versicherungsbestätigung
ausgestellt wurde oder auf die sie
sich bezieht, besteht
Versicherungsschutz nur im Rahmen
und Umfang des beschriebenen
Versicherungsvertrages. Die
aufgeführten Deckungssummen können
durch Schadenzahlungen reduziert
sein.

Die Versicherungsbestätigung wird
zu Informationszwecken ausgestellt
und überträgt keinerlei Rechte auf
den Empfänger. Die
Versicherungsbestätigung ändert
oder erweitert den Deckungsumfang
des beschriebenen
Versicherungsvertrages nicht.

	 	Notwithstanding any requirement,
term or condition of any contract or
other document with respect to which
this certificate may be issued or
may pertain, the insurance afforded
by the policy described herein is
subject to all terms, exclusions and
conditions of such policy. Limits
shown may have been reduced by paid
claims.

The certificate is issued as a
matter of information only and
confers no rights upon the
certificate holder. This
certificates does not amend, extend
or alter the coverage afforded by
policy described herein.
	 
	 	 
	Bestätigung der Versicherer:

	 	Confirmation of Insurer
	 
	 	 
	Siehe Anlagen

	 	Please compare the enclosure.

57

 

Aon Jauch & Hiibener

	 	 	 	 	 	 	 

	Bestätigung der Versicherer:	 	Confirmation of Insurer
	 
	 	 	 	 	 	 
	Versicherungsschein Nr.	 	Policy No.	 	 
	Betriebshaftpflicht

	 	70-5385726,
	 	General Liability
	 	70-5385726,
	1. Anschluss

	 	70-5563377
	 	1. Excess
	 	70-5563377
	2. Anschluss

	 	70-5563378
	 	2. Excess
	 	70-5563378
	3. Anschluss

	 	70-5883228
	 	3. Excess
	 	70-5883228
	 
	 	 	 	 	 	 
	Wir bestätigen für unseren 67% igen Anteil	 	We confirm for our share of 67%.

Gerling Allgemeine Versicherungs AG

Düsseldorf

GERLING-KONZERN

Allgemeine Versicherungs-Akiengesellschaft

Bevollmächtigte:

GERLING Vertrieb Deutschland GmbH

Regionalzentrum West

58

 

Aon Jauch & Hiibener

	 	 	 	 	 	 	 

	Versicherungsschein Nr.	 	Policy No.	 	 
	 
	 	 	 	 	 	 
	Betriebshaftpflicht

	 	70-5385726,
	 	General Liability
	 	70-5385726,
	1. Anschluss

	 	70-5563377
	 	1. Excess
	 	70-5563377
	2. Anschluss

	 	70-5563378,
	 	2. Excess
	 	70-5563378
	3. Anschluss

	 	70-5883228
	 	3. Excess
	 	70-5883228
	 
	 	 	 	 	 	 
	Wir bestätigen für unseren 33% igen Anteil	 	We confirm for our share of 33%.

XL Insurance Company Ltd.

Direction of Germany

München

59

 

ANNEX H QUALITY AGREEMENT

(to be attached after execution of the quality agreement)

60

 

QUALITY ASSURANCE AGREEMENT

Between NuPathe Inc and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples

	 	 	 

	Between:

	 	NuPathe Inc
	 

	 	375 E. Elm Street, Suite 110
	 

	 	Conshohocken, PA 19428, USA
	 
	 	 
	 

	 	- Receiving Party -
	 
	 	 
	 

	 	- hereinafter referred to as NuPathe-
	 
	 	 
	 

	 	and
	 
	 	 
	 

	 	LTS Lohmann Therapie-Systeme AG
	 

	 	Lohmannstr. 2
	 

	 	56626 Andernach, Germany
	 
	 	 
	 

	 	- Manufacturer -
	 
	 	 
	 

	 	- hereinafter referred to as LTS -
	 
	 	 
	- an agreement is made as follows:

 

 

	 	 	 	 	 
	CONTENT	 	 	 	 
	 
	PREAMBLE 3
	 	 	 	 
	§ 1  DEFINITIONS
	 	 	3	 
	§ 2  BASIS OF AGREEMENT
	 	 	4	 
	§ 3  SUBJECT MATTER OF AGREEMENT
	 	 	5	 
	§ 4  AUTHORIZATION DOCUMENTS
	 	 	5	 
	§ 5  STARTING MATERIALS
	 	 	5	 
	§ 6  ORDERING
	 	 	6	 
	§ 7  PRODUCTION
	 	 	7	 
	§ 8  QUALITY CONTROL
	 	 	7	 
	§ 9  BATCH PRODUCTION AND CONTROL RECORDS
	 	 	7	 
	§ 10  BATCH ACCOMPANYING DOCUMENTS
	 	 	8	 
	§ 11  REFERENCE AND RETENTION SAMPLES OF THE PRODUCTS
	 	 	8	 
	§ 12  RELEASE
	 	 	8	 
	§ 13  QUALIFICATIONS/TRAINING
	 	 	9	 
	§ 14  THIRD PARTIES
	 	 	9	 
	§ 15  INSPECTIONS
	 	 	9	 
	§ 16  QUALITY DEFECTS — PRODUCT COMPLAINTS
	 	 	10	 
	§ 17  DEVIATIONS — INVESTIGATIONS
	 	 	10	 
	§ 18  PERSONS TO CONTACT
	 	 	10	 
	§ 19  CONFIDENTIALITY
	 	 	10	 
	§ 20  FINAL PROVISIONS
	 	 	10	 
	LIST OF APPENDICES
	 	 	12	 

 

 

QUALITY ASSURANCE AGREEMENT

Between NuPathe Inc and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples

PREAMBLE

The purpose of this Agreement is to make sure that Manufacturer and Receiving Party are in
compliance with the applicable legal provisions relating to the manufacture of pharmaceutical
products, such as 2003/94/EC, Article 12 and related national laws, in particular AMWHV § 9, as
well as applicable U.S. federal regulations, including those promulgated by the FDA.

This Agreement shall make sure that quality functions as required by law are taken care in an
appropriate manner. It is not the intention of this Agreement to alter and/or amend any agreement,
included but not limited to the Legal Contract (as defined below) which is directly or indirectly
the basis for the supply of product to Receiving Party.

This Agreement shall be used only in order to comply with regulations applicable to the
responsibilities of pharmaceutical manufacturers and suppliers. Except to the extent set forth in
the Legal contract, nothing in this Agreement shall be construed to establish any financial or
other direct or indirect liability with regard to the other party or regarding the liability for
any third party claims related to the Product. The commercial basis of the relationship between
the parties as set forth in the Development Agreement shall continue to apply.

§ 1 DEFINITIONS

	 	(1)	 	Capitalized terms used herein and not otherwise defined herein, shall have
the meanings set forth in the Legal Contract.
	 
	 	(2)	 	“Authorities” shall mean the governmental authorities, which are responsible
for the approval of the Product in a certain jurisdiction and/or the surveillance of
the Product in such a jurisdiction.
	 
	 	(3)	 	“Legal Contract” shall mean the letter agreement concluded between NuPathe
and LTS as of October 26th, 2006.
	 
	 	(4)	 	“Master Manufacturing Instructions” shall mean the manufacturing instructions
for a Product, as set forth in the IMPD.
	 
	 	(5)	 	IMPD shall mean Investigational Medicinal Product Dossier
	 
	 	(6)	 	“Product” shall mean each of the products listed in Appendix I.
	 
	 	(7)	 	“Responsible” and/or “Responsibility” shall mean assignment of tasks and
shall not have any effect on the liability of the parties.

 

 

QUALITY ASSURANCE AGREEMENT

Between NuPathe Inc and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples

	 	(8)	 	“Specifications” shall mean the specifications of the Product mutually agreed
upon, as set forth in the Master Manufacturing Instructions.
	 
	 	(9)	 	“Starting Materials” shall mean:

	 	•	 	raw materials: active and inactive ingredients necessary for the production
of the Products;
	 
	 	•	 	materials that, although no longer contained in the Product, were used for
the manufacture of the Product (e.g. water, organic solvents); and
	 
	 	•	 	packaging materials.

	 	 	 	Those are listed in the Master Manufacturing Instructions.

	 	(10)	 	“Starting Materials Specifications” shall mean the specifications of the
Starting Materials laid down in the Master Manufacturing Instructions.
	 
	 	(11)	 	Iontophoretic Components in terms of this Quality Agreement is not defined as
starting material, but as an own class of components.
	 
	 	(12)	 	“Test Methods” shall mean the test methods listed in the Master Manufacturing
Instructions.

§ 2 BASIS OF AGREEMENT

	 	(1)	 	This Agreement is based on the Legal Contract. This Agreement is in general
appended to the Legal Contract between NuPathe and LTS which covers the commercial and
other aspects including the costs for special activities and secrecy agreements, and
does not amend, supply or otherwise modify the Legal Contract. In the event of
inconsistency between this Agreement and the Legal Contract, the Legal Contract shall
prevail.
	 
	 	(2)	 	LTS is a manufacturer of pharmaceutical products, having a manufacturing
authorization in accordance with the German Drug Law (AMG) §13 and being subject to
monitoring by the competent authorities.
	 
	 	 	 	LTS complies with all currently applicable rules regarding the manufacture of
pharmaceutical products, such as the “Good Manufacturing Practices, Medicinal
Products for Human and Veterinary Use” contained in Vol. IV of “the Rules Governing
Medicinal Products in the European Union”, including all relevant annexes; Good
Manufacturing

 

 

QUALITY ASSURANCE AGREEMENT

Between NuPathe Inc and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples

	 	 	 	Practices for Pharmaceutical Products, published by WHO and relevant
additional and supplementary guidelines, GMP rules published in 21 CFR Part 210 and
21 CFR Part 211.
	 
	 	(3)	 	NuPathe is a developer of pharmaceutical products, having authorization in
accordance with relevant pharmaceutical law and being subject to monitoring by the
competent authorities.
	 
	 	 	 	NuPathe complies with all currently applicable rules regarding the
development of pharmaceutical products such as “Good Manufacturing Practices,
Medicinal Products for Human and Veterinary Use” contained in Vol. IV of “the Rules
Governing Medicinal Products in the European Union”, including all relevant
annexes; Good Manufacturing Practices for Pharmaceutical products, published by WHO
and relevant additional and supplementary guidelines, GMP rules published in 21 CFR
Part 210 and 21 CFR Part 211.

§ 3 SUBJECT MATTER OF AGREEMENT

	 	 	LTS shall be Responsible for the manufacturing of the Products as set forth in Appendix I
“List of Products” for NuPathe
	 
	 	 	The functions and Responsibilities of the parties are as set forth in Appendix II
(“Overview of Functions and Responsibilities”).

§ 4 AUTHORIZATION DOCUMENTS

	 	 	NuPathe shall provide LTS with the IMPD or comparable documents. NuPathe shall immediately
inform LTS of any changes to the IMPD or comparable documents and provide LTS with a copy
of such changed IMPD or comparable documents.

§ 5 STARTING MATERIALS

	 	(1)	 	Purchase

	 	 	The Responsibility for the purchase of the Starting Materials is given in Appendix II.

	 	(2)	 	Quality control

	 	 	LTS shall be Responsible for the quality of the Starting Materials purchased by LTS and
will therefore analyze these Starting Materials with regard to the Starting Material
Specification.

 

 

QUALITY ASSURANCE AGREEMENT

Between NuPathe Inc and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples

	 	 	To the extent that NuPathe wishes additional analyses, NuPathe shall inform LTS. LTS will
provide NuPathe with an offer.
	 
	 	 	The quality of the Starting Materials made available by NuPathe shall be certified by
NuPathe in form of a Certificate of Analysis which shall accompany the shipment of each
batch of Starting Materials.
	 
	 	 	LTS’ Responsibility for the quality of the Starting Materials made available by NuPathe
shall include the verification — upon receipt of the Starting Materials — of at least the
following:

	 	i)	 	Intactness of the container and closure
	 
	 	ii)	 	Congruence of the labeling with the delivery notes
	 
	 	iii)	 	Identity testing of the content

	 	(3)	 	Storage
	 
	 	 	 	LTS shall be Responsible for the storage of all Starring Materials in such manner
that the quality of such Starting Material is not affected.
	 
	 	(4)	 	Reference and retention samples
	 
	 	 	 	LTS is Responsible for keeping reference and retention samples of each batch of
Starting Materials, other than solvents, gases or water, used for clinical samples
that LTS purchases. These samples shall be retained for at least two years after
the release of Product. The amount of reference and retention samples must be such
that it is possible to perform two (2) full quality control analyses (without
microbiological testing).
	 
	 	(5)	 	Suppliers
	 
	 	 	 	LTS will utilize only materials and components from only suppliers, which have been
approved by NuPathe. If the qualification of a new supplier is necessary, both LTS
and NuPathe are Responsible for the qualification activities.

§ 6 ORDERING

	 	 	NuPathe shall provide a specific order for each batch, specifying:

 

 

QUALITY ASSURANCE AGREEMENT

Between NuPathe Inc and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples

	 	a.	 	Current production formulae
	 
	 	b.	 	Master Manufacturing Instructions
	 
	 	c.	 	Storage conditions and packaging instructions for the
shipments of Products Such orders to be attached as Appendix III, “Formula
Assignment for Clinical Trials and Manufacturing Order”.

§ 7 PRODUCTION

	 	 	LTS shall be Responsible for the manufacturing of the Products according to the Master
Manufacturing Instructions.

§ 8 QUALITY CONTROL

	 	 	LTS shall be Responsible for compliance of the Products delivered by LTS with the
Specifications as defined by the IMPD.
	 
	 	 	For the judgement of compliance with the Specifications the results obtained with the Test
Methods are relevant. In case of contradictory results a mutual agreed external analytical
institute (Third Party) will be ordered for an investigation.

§ 9 BATCH PRODUCTION AND CONTROL RECORDS

	 	 	LTS shall be Responsible for retaining the batch documentation for the investigational
medicinal product for at least seven years after the release of Product at LTS. NuPathe
shall be Responsible for informing LTS if the completion or formal discontinuation of the
last clinical trial in which the batch was used extends beyond two years from the date of
release of Product at LTS. NuPathe shall be Responsible for ensuring that records are
retained as required for marketing authorisation in accordance with the Annex I to
Directive 2001/83/EC, if required for a subsequent marketing authorisation.

	 	 	The batch production and control record shall include, without limitation, the following:

	 	-	 	Name and form of Product;
	 
	 	-	 	Batch number of Product being manufactured;
	 
	 	-	 	Dates and times of commencements of significant intermediate stages and of the completion
of production;
	 
	 	-	 	Batch number or test number and amounts of each Starting Material used;

 

 

QUALITY ASSURANCE AGREEMENT

Between NuPathe Inc and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples

	 	-	 	Equipment used including cleaning confirmation;
	 
	 	-	 	Any relevant processing operation or event and its confirmation by signing
of the responsible operators;
	 
	 	-	 	Deviation reports and OOS investigations;
	 
	 	-	 	The theoretical and actual yields of major steps in the processing, detailed information
on deviations, exceptional occurrences, e.g. defects and their repairs, signed by an
authorized person;
	 
	 	-	 	Test reports of intermediates, bulk ware;
	 
	 	-	 	Results of in-process controls and laboratory testing and decisions following these
results;
	 
	 	-	 	Signature of the responsible production and quality control manager.
	 
	 	-	 	Signature of the Qualified Person

	 	 	Test reports of raw materials are separate archived in the Quality Control Lab.

§ 10 BATCH ACCOMPANYING DOCUMENTS

	 	 	LTS shall be Responsible for delivering with every batch a Certificate of Compliance
(Appendix IV) and other batch accompanying documents such as
Certificate of Production Compliance and Certificate of Analysis (both Appendix IV)
according to the Specifications.

§ 11 REFERENCE AND RETENTION SAMPLES OF THE PRODUCTS

	 	 	LTS is Responsible for keeping reference and retention samples of each batch of Product of
this Agreement. These samples shall be retained for at least four years after the release
of Product at LTS. NuPathe shall be Responsible for informing LTS if the completion or
formal discontinuation of the last clinical trial in which the batch was used, whichever
period is the longer, extends beyond two years from the date of release of Product at LTS.
The amount of reference and retention samples must be such that it is possible to perform
at least 2 full quality control analyses (without microbiological testing). LTS is also
Responsible for the keeping of samples which are mandatory by law.

§ 12 RELEASE

	 	 	The release of the bulk Product for shipment to NuPathe is in the Responsibility

 

 

QUALITY ASSURANCE AGREEMENT

Between NuPathe Inc and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples

		 	of LTS. Final release of the Product is in the Responsibility of NuPathe.

§ 13 QUALIFICATIONS/TRAINING

	 	 	LTS is Responsible for training all of its personnel involved in the Manufacture of Product
and the documentation of such training.

§ 14 THIRD PARTIES

	 	 	LTS may employ third parties with the execution of the tasks given to it by this Agreement.
The names of any such third parties and their duties delegated to them shall be listed in
the Overview of Functions and Responsibilities set forth in Appendix II. LTS is
Responsible for the quality of the Product and all legal requirements connected therewith
and such Responsibility cannot be transferred to a third party.

§ 15 INSPECTIONS

	 	 	LTS agrees that NuPathe has the right to audit the premises where the Products are
manufactured, including packaging, storage, quality control and distribution.
	 
	 	 	These audits will be scheduled at a time mutually convenient to both parties.
	 
	 	 	Audits by NuPathe during production of non NuPathe products are excluded with respect to
secrecy agreements with third parties. Mutually agreed upon corrective actions resulting
from the observations made during the inspection have to be performed as quickly as
reasonably practicable. LTS will report to NuPathe about its efforts in the carrying out
of the corrective actions within a time frame mutually agreed upon by the parties. LTS
shall use its commercially reasonable efforts to support NuPathe at the occasion of
inspections at NuPathe performed by drug monitoring authorities.
	 
	 	 	LTS shall be Responsible for the qualification and inspection of third parties if
necessary. They are also subject of inspections by NuPathe. The latter inspections shall
be performed only in the presence of LTS. The centralized control for these third-party
inspections shall be in the Responsibility of LTS. This encompasses the scheduling as well
as the surveillance concerning corrective actions. .NuPathe shall not contact the third
party directly without LTS’ written consent.
	 
	 	 	LTS will provide NuPathe with copies of any FDA 483 reports or any similar reports relating
to the Product.

 

 

QUALITY ASSURANCE AGREEMENT

Between NuPathe Inc and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples

§ 16 QUALITY DEFECTS — PRODUCT COMPLAINTS

	 	 	Both parties agree to contact each other immediately as soon as they become aware of
quality defects after shipment.
	 
	 	 	NuPathe will be Responsible for handling all complaints; regardless of source, will
coordinate all customer-related Activities involving complaints, and will maintain the
complete complaint database and complaint files. NuPathe will forward complaint
information to LTS when a technical investigation is required.

§ 17 DEVIATIONS — INVESTIGATIONS

	 	(1)	 	Deviations
	 
	 	 	 	LTS shall be Responsible to record in the Product batch file any deviation to the
manufacturing process and to inform NuPathe about all deviations which will have to
the best of the knowledge of LTS relevant influence on the quality of the Product
and do not result in a rejection by LTS itself. NuPathe shall be notified of such
deviations prior to LTS release of bulk Product. It is LTS’ Responsibility that
each deviation will be justified and approved by LTS’s Qualified Persons.
	 
	 	(2)	 	Investigations and solutions to problems
	 
	 	 	 	LTS is Responsible to conduct an investigation for each OOS result which may occur.
It is LTS’ Responsibility that each investigation will be assessed and approved by
LTS’s Qualified Person.

§ 18 PERSONS TO CONTACT

	 	 	The relevant persons who should be contacted in case of questions that may arise concerning
all pharmaceutical/technical matters which are subject of this Agreement are listed in
Appendix V (“Persons to Contact”).

§ 19 CONFIDENTIALITY

	 	 	LTS and NuPathe agree to keep proprietary information of each other, including but not
limited to know-how and Master Manufacturing Instructions confidential in accordance with §
11 of the Legal Contract.

§ 20 FINAL PROVISIONS

	 	(1)	 	This Agreement shall become effective upon its signature by the parties and
shall have a duration corresponding to the Legal Contract.

 

 

QUALITY ASSURANCE AGREEMENT

Between NuPathe Inc and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples

	 	(2)	 	This Agreement and any Appendices hereto may be amended or modified only by
written agreement executed by duly authorized officers of the parties hereto.
	 
	 	(3)	 	This Agreement and all appendices attached hereto contain the entire
understanding of the parties pertaining to the subject matter hereof.
	 
	 	(4)	 	Supplementary agreements are listed to the extent that they exist in Appendix
VI (“Supplementary Agreements”).
	 
	 	(5)	 	All appendices attached to this Agreement are incorporated by reference
herein and made a part hereof.
	 
	 	(6)	 	Upon the request of competent authorities, relevant parts of this Agreement
may be forwarded to the competent authorities. The party receiving such a request
shall notify the other party to this Agreement before complying with the information
request.
	 
	 	(7)	 	If any provision of this Agreement is held to be illegal, invalid or
unenforceable under any applicable present or future law, such provision shall be
fully severable and shall be replaced by a provision which comes as close to the
intended provision as is possible. The parties agree to inform and consult each other
if a party is in doubt regarding the validity of a provision of this Agreement and
shall not take any advantages of such doubts. Headings in this Agreement are included
for ease of reference only and have no legal effects.
	 
	 	(8)	 	This Agreement shall be governed by and construed in accordance with the laws
of the Federal Republic of Germany, regardless of the laws that might otherwise govern
under applicable principles of conflicts of laws thereof. In no event shall choice of
law analysis lead to the application of any other than German law.
	 
	 	(9)	 	As set forth in the Legal Contract, all disputes arising out of or in
connection with the present agreement and any subsequent agreement shall be finally
settled under the Rules of Arbitration of the International Chamber of Commerce by one or more arbitrators appointed in accordance with the
said Rules.
	 
	 	(10)	 	As set forth in the Legal Contract, the Arbitration shall be held in Toronto,
Canada or any other place that the parties may agree upon. The arbitration shall be
conducted in English. The award of arbitration shall be final and binding upon both
parties.

 

 

QUALITY ASSURANCE AGREEMENT

Between NuPathe Inc and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples

	 	(11)	 	In the event that any dispute or claim of any sort arising out of this
Agreement and / or any dispute or claim concerning competent court and / or
jurisdiction and / or execution of any award granted by a foreign court or arbitration
panel should lie in a jurisdiction in which trial by jury is standard or may be
demanded, each of the parties irrevocably waives any right to demand or request a
trial by jury and agrees to take such further action as it is necessary to petition or
apply for a trial without a jury.

LIST OF APPENDICES

	 	 	 

	Appendix I

	 	List of Products
	Appendix II

	 	Overview of Functions and Responsibilities
	Appendix III

	 	Formula Assignment for Clinical Trials and Manufacturing Order
	Appendix IV

	 	Batch Accompanying Documents
	Appendix V

	 	Persons to Contact
	Appendix VI

	 	Supplementary Agreements

	 	 	 	 	 	 	 

	Conshohocken, PA USA

	 	 	 	Andernach, Germany	 	 
	 
	 	 	 	 	 	 
	July 10, 2007

	 	 	 	July 10 2007	 	 
	 
	 	 	 	 	 	 
	NuPathe

	 	 	 	LTS Lohmann Therapie-Systeme AG	 	 
	 
	 	 	 	 	 	 
	/s/ Terri B. Sebree
 

	 	 	 	/s/ K.-H. Meyer
 

	 	 
	Terri B. Sebree

	 	 	 	Dr. K.-H. Meyer	 	 
	President

	 	 	 	Qualified Person	 	 
	 
	 	 	 	 	 	 
	/s/ Suzanne M. Hanlon for
 

	 	 	 	12.07.07 /s/ Guido Müller
 

	 	 
	Amy Chandler-Skerkis

	 	 	 	Dr. Guido Müller	 	 
	VP, Quality Assurance

	 	 	 	Head of Quality Control	 	 

 

 

QUALITY ASSURANCE AGREEMENT

Between NuPathe Inc and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples

	 	 	 	 	 	 	 

	12 Jul. 2007 /s/ Michele Coulaloglou
 

	 	 	 	12.07.07 /s/ U. Riebe
 

	 	 
	Michele Coulaloglou

	 	 	 	Dr. U. Riebe	 	 
	Sr. Project Manager, CMC

	 	 	 	Head of Production — Clinical Samples	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	/s/ H.J. Holley
 

	 	 
	 

	 	 	 	Dr. H.J. Holley	 	 
	 

	 	 	 	Head of Quality Assurance	 	 

 

 

LIST OF APPENDICES pertaining to the QUALITY ASSURANCE AGREEMENT

between NuPathe and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples dated July 10, 2007

LIST OF APPENDICES

	 	 	 	 	 	 	 
	Appendix	 	 	 	Revision	 	Date
	I
	 	List of Products	 	00	 	 
	II
	 	Overview of Functions and Responsibilities	 	00	 	 
	III
	 	Formula Assignment for Clinical Trials	 	00	 	 
	 
	 	and Manufacturing Order	 	 	 	 
	IV
	 	Batch Accompanying Documents	 	00	 	 
	V
	 	Persons to Contact	 	00	 	 
	VI
	 	Supplementary Agreements	 	00	 	 

	 	 	 	 	 	 	 
	Approved by:	 	 	 	Revision: 00	 	 
	NuPathe (Date, Signature)

	 	 	 	LTS (Date, Signature)	 	 
	 
	 	 	 	 	 	 
	/s/ Terri B. Sebree
 

	 	 	 	12.07.2007 /s/ U. Riebe
 

	 	 
	Terri B. Sebree (President)

	 	 	 	Dr. U.
Riebe (Head of Manufacturing — Clinical

Samples)	 	 
	 
	 	 	 	 	 	 
	12.Jul. 2007 /s/ Michele Coulaloglou
 

	 	 	 	11.7.2007 /s/ K.-H. Meyer
 

	 	 
	Michele Coulaloglou (Sr. Project Manager, CMC)

	 	 	 	Dr. K.-H. Meyer (Qualified Person)	 	 
	 
	 	 	 	 	 	 
	/s/ Suzanne M. Hanlon for
 

	 	 	 	11.7.2007 /s/ H.J. Holley
 

	 	 
	Amy Chandler-Skerkis (VP, Quality Assurance)

	 	 	 	Dr. H.J. Holley (Head of Quality Assurance)	 	 

 

 

APPENDIX I pertaining to the QUALITY ASSURANCE AGREEMENT

between NuPathe and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples dated July 10, 2007

APPENDIX I

List of Products

Clinical samples of drug formulations ([**]) for use in iontophoretic patch.

 

	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

	 	 	 	 	 	 	 
	Approved by:	 	 	 	Revision: 00	 	 
	NuPathe (Date, Signature)

	 	 	 	LTS (Date, Signature)	 	 
	 
	 	 	 	 	 	 
	/s/ Suzanne M. Hanlon — for
 

	 	 	 	12.07.2007 /s/ U. Riebe
 

	 	 
	Amy Chandler-Skerkis (VP, Quality Assurance)

	 	 	 	Dr. U.
Riebe (Head of Manufacturing — Clinical

Samples)	 	 
	 
	 	 	 	 	 	 
	/s/ Terri B. Sebree
 

	 	 	 	11.7.2007 /s/ K.-H. Meyer
 

	 	 
	Terri B. Sebree (President)

	 	 	 	Dr. K.-H. Meyer (Qualified Person)	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	11.7.2007 /s/ H.J. Holley
 

	 	 
	 

	 	 	 	Dr. H.J. Holley (Head of Quality Assurance)	 	 

Page 1 of 1

 

APPENDIX II pertaining to the QUALITY ASSURANCE AGREEMENT

between NuPathe and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples dated July 5, 2007

APPENDIX II

Overview of Functions and Responsibilities

	 	 	 	 	 

	Company

	 	LTS
	 	Third Party
	 

	 	Lohmann Therapie-System AG	 	 
	 

	 	Lohmannstrasse 2	 	 
	 

	 	56626 Andernach	 	 
	 

	 	Germany	 	 
	 
	 	 	 	 
	Product:

	 	(see Appendix I)	 	 

	 	 	 	 	 	 	 
	Responsibilities	 	NuPathe	 	LTS	 	Third Party
	I. MATERIALS
	 	 	 	 	 	 
	1. STARTING MATERIALS (without active ingredients)
	 	 	 	 	 	 
	• Quality specifications, testing standards
	 	 	 	X	 	 
	• Purchase and shipment
	 	 	 	X	 	 
	• Testing and release of starting
materials supplied by agreed upon
suppliers
	 	 	 	X	 	 
	• Testing and release of starting
materials supplied by third parties
	 	 	 	X	 	 
	• Retention of batch documentation
	 	 	 	X	 	 
	• Reference and retention samples
	 	 	 	X	 	 
	 
	 	 	 	 	 	 
	2. ACTIVE PHARMACEUTICAL INGREDIENTS
	 	 	 	 	 	 
	• Quality specifications, testing standards
	 	 	 	X	 	 
	• Purchase
	 	X	 	 	 	 
	• Safety data sheet
	 	X	 	 	 	 
	• Testing and release of active
pharmaceutical ingredient(s) supplied by
	 	 	 	 	 	PPD
	• Identity test for correct arrival
	 	 	 	X	 	 
	• Retention of test documentation
	 	 	 	X	 	PPD
	• Reference and retention samples
	 	 	 	X	 	 
	• Shipment responsibilities
	 	X	 	 	 	 
	 
	 	 	 	 	 	 

Page 1 of 4

 

APPENDIX II pertaining to the QUALITY ASSURANCE AGREEMENT

between NuPathe and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples dated July 5, 2007

	 	 	 	 	 	 	 

	3. PRIMARY PACKAGING MATERIALS
	 	 	 	 	 	 
	• Quality specifications, testing standards
	 	 	 	X	 	 
	• Purchase
	 	 	 	X	 	 
	• Testing and release of primary packaging materials
	 	 	 	X	 	 
	• Approval of master for printed packaging materials
	 	 	 	X	 	 
	• Retention of batch documentation
	 	 	 	X	 	 
	• Reference and retention samples
	 	 	 	X	 	 
	• Shipment responsibilities
	 	 	 	X	 	 
	 
	 	 	 	 	 	 
	4. SECONDARY PACKAGING MATERIALS
	 	 	 	 	 	 
	• Quality specifications, testing standards
	 	 	 	X	 	 
	• Purchase of secondary packaging material
	 	 	 	X	 	 
	• Purchase of label material
	 	 	 	X	 	 
	• Testing and release of secondary packaging materials
	 	 	 	X	 	 
	• Approval of master for printed packaging materials
	 	 	 	X	 	 
	• Retention of batch documentation
	 	 	 	X	 	 
	• Reference and retention samples
	 	 	 	X	 	 
	• Shipment responsibility
	 	 	 	X	 	 
	 
	 	 	 	 	 	 
	5. INTERMEDIATE PRODUCTS — LAMINATE
	 	 	 	NA	 	 
	• IPC, testing standards
	 	 	 	 	 	 
	• Retention of batch documentation
	 	 	 	 	 	 
	• Storage conditions
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	6. PRIMARY PACKAGED PRODUCT
	 	 	 	 	 	 
	• Quality specifications, testing standard
	 	 	 	X	 	 
	• Testing and release of primary package product for
shipment to clinical site as defined in formula
assignment
	 	 	 	X	 	 
	• Purchase of label material
	 	 	 	X	 	 
	• Retention of batch documentation
	 	 	 	X	 	 
	• Reference and retention samples
	 	 	 	X	 	 
	• Retention of analytical samples for concurrent
stability testing
	 	 	 	X	 	 
	• Storage conditions
	 	 	 	X	 	 
	• Stability protocol
	 	 	 	X	 	 
	• Performance of stability study
	 	 	 	X	 	 
	• Stability Report
	 	 	 	X	 	 

Page 2 of 4

 

APPENDIX II pertaining to the QUALITY ASSURANCE AGREEMENT

between NuPathe and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples dated July 5, 2007

	 	 	 	 	 	 	 

	7. FINISHED PRODUCT
	 	 	 	 	 	 
	• Quality specifications, testing standard
	 	 	 	X	 	 
	• Retention of batch documentation
	 	 	 	X	 	 
	• Reference and retention samples
	 	 	 	X	 	 
	• Reference and retention samples mandatory by law
	 	 	 	X	 	 
	• Shipment responsibility
	 	X	 	X	 	 
	• Testing and release of finished product
	 	 	 	X	 	 
	• Certificate of Analysis for each batch
	 	 	 	X	 	—
	• Certificate of Compliance for each batch
	 	 	 	X	 	 
	• Stability protocol
	 	 	 	X	 	 
	• Performance of stability study
	 	 	 	X	 	 
	• Stability report
	 	 	 	X	 	 
	 
	 	 	 	 	 	 
	II. PROCESSES, PROCEDURES
	 	 	 	 	 	 
	8. PRODUCTION OF PRIMARY PACKAGED PRODUCT
	 	 	 	 	 	 
	• Validation/qualification of analytical
methods and equipment used including
documentation
	 	 	 	X	 	 
	• Manufacturing documentation
	 	 	 	X	 	 
	• Specifications of materials
	 	 	 	X	 	 
	• Processing instructions
	 	 	 	X	 	 
	• In-process controls
	 	 	 	X	 	 
	• Testing and release of primary packaged
product
	 	 	 	X	 	 
	• Certificate of Compliance for each batch
	 	 	 	X	 	 
	• Certificate of Analysis for each batch
	 	 	 	X	 	 
	• Retention of batch documentation
	 	 	 	X	 	 
	• Reference and retention samples
	 	 	 	X	 	 
	 
	 	 	 	 	 	 
	9. PACKAGING
	 	 	 	 	 	 
	• Specifications of materials
	 	 	 	X	 	 
	• Packaging instructions primary packaging
	 	 	 	X	 	 
	• Packaging instructions secondary packaging
	 	 	 	X	 	 
	• Labeling of primary packaged product including IPC
	 	 	 	X	 	 
	• Secondary packaging and labeling including IPC
	 	 	 	X	 	 
	• Retention of batch packaging records for
primary packaging
	 	 	 	X	 	 

Page 3 of 4

 

APPENDIX II pertaining to the QUALITY ASSURANCE AGREEMENT

between NuPathe and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples dated July 5, 2007

	 	 	 	 	 	 	 

	• Retention of batch packaging records for
secondary packaging
	 	 	 	X	 	 
	• Release and distribution of finished product for
clinical study
	 	X	 	X	 	 
	 
	 	 	 	 	 	 
	10. COMPLAINTS
	 	 	 	 	 	 
	• Registration of complaints from customer
	 	X	 	 	 	 
	• Investigation of complaints
	 	X	 	 	 	 
	• Corrective actions
	 	X	 	 	 	 
	• Answer to complaint to customer
	 	X	 	 	 	 
	• Documentation
	 	X	 	 	 	 

	 	 	 	 	 	 	 
	Approved by:	 	 	 	Revision: 00	 	 
	NuPathe (Date, Signature)

	 	 	 	LTS (Date, Signature)	 	 
	 
	 	 	 	 	 	 
	/s/ Suzanne M. Hanlon — for
 

	 	 	 	12.07.2007 /s/ U. Riebe
 

	 	 
	Amy Chandler-Skerkis (VP, Quality Assurance)

	 	 	 	Dr. U. Riebe (Head of Manufacturing — Clinical
Samples)	 	 
	 
	 	 	 	 	 	 
	12 Jul. 07/s/ Terri B. Sebree
 

	 	 	 	11.07.2007 /s/ K.-H. Meyer
 

	 	 
	Terri B. Sebree (President)

	 	 	 	Dr. K.-H. Meyer (Qualified Person)	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	11.7.2007 /s/ H.J. Holley
 

	 	 
	 

	 	 	 	Dr. H.J. Holley (Head of Quality Assurance)	 	 

Page 4 of 4

 

APPENDIX III pertaining to the QUALITY ASSURANCE AGREEMENT

between NuPathe and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples dated July 5, 2007

APPENDIX III

Formula Assignment for Clinical Trials and Manufacturing Order

(see Attachment)

	 	 	 	 	 

	Approved by:

	 	 	 	Revision: 00
	 
	 	 	 	 
	NuPathe (Date, Signature)

	 	 	 	LTS (Date, Signature)
	 
	 	 	 	 
	/s/ Michele Coulaloglou
 

Michele Coulaloglou (Sr. Project Manager, CMC)

	 	 	 	12.07.2007 /s/ U. Riebe
 
 Dr. U.
Riebe (Head of Manufacturing — Clinical Samples)
	 
	 	 	 	 
	12 Jul. 2007 /s/ Terri B. Sebree
 

Terri B. Sebree (President)

	 	 	 	11.7.2007 /s/ K.-H. Meyer
 
 Dr. K.-H.
Meyer (Qualified Person)
	 
	 	 	 	 
	 
 

	 	 	 	11.7.2007 /s/ H.J. Holley
 
 Dr. H.J.
Holley (Head of Quality Assurance)
	 
	 	 	 	 

Page 1of 1

 

APPENDIX IV pertaining to the QUALITY ASSURANCE AGREEMENT

between NuPathe and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples dated July 5, 2007

APPENDIX IV

Batch Accompanying Documentation

The following documents shall be forwarded to NuPathe with each delivery of the product

	 	1.	 	Certificate of Production Compliance
	 
	 	2.	 	Certificate of Analysis
	 
	 	3.	 	Certificate of Compliance
	 
	 	4.	 	Deviation Reports (if not “no risk” or “minor” classification)

	 	 	 	 	 

	Approved by:

	 	 	 	Revision: 00
	 
	 	 	 	 
	NuPathe (Date, Signature)

	 	 	 	LTS (Date, Signature)
	 
	 	 	 	 
	/s/ Suzanne M. Hanlon — for
 

Amy Chandler-Skerkis (VP, Quality Assurance)

	 	 	 	12.07.2007 /s/ U. Riebe
 
 Dr. U.
Riebe (Head of Manufacturing — Clinical Samples)
	 
	 	 	 	 
	12 Jul. 2007 /s/ Terri B. Sebree
 

Terri B. Sebree (President)

	 	 	 	11.7.2007 /s/ K.-H. Meyer
 
 Dr. K.-H.
Meyer (Qualified Person)
	 
	 	 	 	 
	 
 

	 	 	 	11.7.2007 /s/ H.J. Holley
 
 Dr. H.J.
Holley (Head of Quality Assurance)
	 
	 	 	 	 

Page 1of 1

 

APPENDIX V pertaining to the QUALITY ASSURANCE AGREEMENT

between NuPathe and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples dated July 5, 2007

APPENDIX V

Persons to Contact

LTS Lohmann Therapie-Systeme AG

[**]

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

	 	 	 	 	 

	NuPathe (Date, Signature)

	 	 	 	Revision: 00
	 
	 	 	 	 
	12 Jul. 2007 /s/ Michele Coulaloglou
 

Michele Coulaloglou (Sr. Project Manager, CMC)

	 	 	 	LTS (Date, Signature 
	 
	 	 	 	 
	12 Jul. 2007 /s/ Terri B. Sebree
 

Terri B. Sebree (President)

	 	 	 	12.07.2007 /s/ U. Riebe
 
 Dr. U.
Riebe (Head of Manufacturing — Clinical Samples)
	 
	 	 	 	 
	 

	 	 	 	11.7.2007 /s/ K.-H. Meyer
 
 Dr. K.-H.
Meyer (Qualified Person
	 
	 	 	 	 
	 

	 	 	 	11.7.2007 /s/ H.J. Holley
 
 Dr. H.J.
Holley (Head of Quality Assurance)

Page 1of 2

 

APPENDIX VI pertaining to the QUALITY ASSURANCE AGREEMENT

between NuPathe and LTS Lohmann Therapie-Systeme AG

on the manufacturing of clinical samples dated July 10, 2007

APPENDIX VI

Supplementary Agreements

Letter Agreement dated October 26, 2006.

	 	 	 	 	 

	Approved by:

	 	 	 	Revision: 00
	 
	 	 	 	 
	NuPathe (Date, Signature)

	 	 	 	LTS (Date, Signature)
	 
	 	 	 	 
	12 Jul. 2007 /s/ Terri B. Sebree

	 	 	 	12.07.2007 /s/ U. Riebe
	 

	 	 	 	 
	Terri B. Sebree (President)

	 	 	 	Dr. U. Riebe (Head of Manufacturing -
Clinical Samples)
	 
	 	 	 	 
	 

	 	 	 	11.7.2007 /s/ K.-H. Meyer
	 

	 	 	 	 
	 

	 	 	 	Dr. K.-H. Meyer (Qualified Person)
	 
	 	 	 	 
	 

	 	 	 	11.7.2007 /s/ H.J. Holley
	 

	 	 	 	 
	 

	 	 	 	Dr. H.J. Holley (Head of Quality Assurance)

Page 1of 1

 

Amendment to Quality Assurance Agreement dated July 12th, 2007 (“QAA”)

between

NuPathe Inc., 375 East Elm Street, Suit 110, Conshohocken, PA 19428, USA (“NuPathe”)

and

LTS Lohmann Therapie-Systeme AG, Lohmannstr. 2, 56626 Andernach, Germany (“LTS”)

WHEREAS, the parties wish to amend the terms and conditions of the QAA for the manufacture of clinical samples by LTS.

Now, therefore, the parties agree as follows:

	1.	 	§ 3 of the QAA shall be amended as follows:
	 
	 	 	LTS shall be Responsible for the manufacturing of the Products as set forth in Appendix 1 “List of Products” for NuPathe.
	 
	 	 	The functions and Responsibilities of the parties are set forth in Appendix 2 (“Overview of functions and responsibilities”).
	 
	 	 	LTS shall be Responsible for the manufacturing of the Iontophoretic patch.
	 
	 	 	NuPathe shall be Responsible for the quality control and the release of the Iontophoretic patch.
	 
	2.	 	All other terms and conditions of the agreement shall remain unaffected.

	 	 	 	 	 

	Conshohocken, PA, USA

	 	 	 	Andernach, Germany
	Nov 6, 2007

	 	 	 	Nov 6, 2007
	NuPathe

	 	 	 	LTS Lohmann Therapie-Systeme AG
	 
	 	 	 	 
	/s/ Terri B. Sebree

	 	 	 	6.11.2007 /s/ . K.-H. Meyer
	 

	 	 	 	 
	Terri B. Sebree

	 	 	 	Dr. K.-H. Meyer
	President

	 	 	 	Qualified Person
	 
	 	 	 	 
	/s/ Amy Chandler-Skerkis 11-6-07

	 	 	 	06/11/2007 /s/ Guido Müeller
	 

	 	 	 	 
	Amy Chandler-Skerkis

	 	 	 	Dr. Guido Müeller
	VP, Quality Assurance

	 	 	 	Head of Quality Control
	 
	 	 	 	 
	/s/ Michele Coulaloglou 6 Nov. 2007

	 	 	 	06.11.2007 /s/ U. Riebe
	 

	 	 	 	 
	Michele Coulaloglou

	 	 	 	Dr. U. Riebe
	Sr. Project Manager, CMC

	 	 	 	Head of Production — Clinical Samples
	 
	 	 	 	 
	 

	 	 	 	06.11.07 /s/ H.J. Holley
	 

	 	 	 	 
	 

	 	 	 	Dr. H.J. Holley
	 

	 	 	 	Head of Quality Assurance

 

 

Amendment to the Development and License Agreement

between LTS LOHMANN Therapie-Systeme AG and NuPathe Inc.,

effective as of September 14th, 2007

This amendment, effective as of April 1st, 2008 (“Effective Date”) by and among LTS
LOHMANN Therapie-Systeme AG, a company organized under the laws of Germany having a principal place
of business at Lohmannstraße 2, 56626 Andernach, Federal Republic of Germany (“LTS”);

and

NuPathe Inc., a corporation organized under the laws of Delaware having a principal place of
business at 375 East Elm Street, Suit 110, Conshohocken, PA 19428, USA (“NuPathe”)

WHEREAS, LTS and NuPathe have concluded a Development and License Agreement effective as of
September 14th, 2007; and

WHEREAS, the parties now wish to amend the terms for the funding of the development work in order
to include a compensation for machine-hours.

NOW THEREFORE, in consideration of the premises and mutual covenants and conditions set forth
herein, the parties agree as follows:

	I.	 	Section 6.2.01 (1) shall be amended as follows:
	 
	 	 	“NuPathe shall compensate LTS for all man- and machine-hours
actually spent by LTS on the project according to the development
plan for development activities, for production testing, scale up
activities and — as applicable — to validation activities, and
registration activities at the rate of € [**] per man-hour, [**],
and € [**] per machine-hour, [**]. For the avoidance of doubt,
NuPathe shall not be obliged to compensate LTS for man-hours spent
on activities for which LTS receives a compensation by
machine-hour.”

	II.	 	All other terms and conditions of the agreement shall remain unaffected.

IN WITNESS WHEREOF, the Parties hereto have executed this Amendment.

	 	 	 	 	 	 	 	 	 

	LTS LOHMANN Therapie-Systeme AG	 	 	 	NuPathe Inc.
	 
	 	 	 	 	 	 	 	 
	/s/ ppa. K. Haczkiewicz	 	 	 	/s/ J. Hollingsworth
	 	 	 	 	   
	Name:

	 	K. Haczkiewicz
	 	 	 	Name:
	 	J. Hollingsworth
	Title: Head of Business Development
	 	 	 	Title: CEO
	Place, Date: Andernach, June 3, 2008
	 	 	 	Place, Date: June 11, 2008
	 
	 	 	 	 	 	 	 	 
	/s/ ppa. U. Sielaff	 	 	 	 	 	 
	   	 	 	 	 	 	 
	Name:

	 	U. Sielaff	 	 	 	 	 	 
	Title: General Counsel	 	 	 	 	 	 
	Place, Date: Andernach, June 4, 2008	 	 	 	 	 	 

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND
WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

 

 

Amendment No 2 to the Development and License Agreement

between LTS LHOMANN Therapie-Systeme AG and Nupathe Inc.

Effective as of September 14, 2007

This amendment, effective as of February 17, 2009 (“Effective Date”) by and among LTS LOHMANN
Therapie-Systeme AG, a company organized under the laws of Germany having a principal place of
business at Lohmannstraße 2, 56626 Andernach, Federal Republic of Germany (“LTS”)

and

NuPathe Inc., a corporation organized under the laws of Delaware having a principal place of
business at 227 Washington Street, Suite 200, Conshohocken, PA 19428 (“NuPathe”)

WHEREAS, LTS and NuPathe have concluded a Development and License Agreement effective as of
September 14, 2007 (the “Agreement”); and

WHEREAS, the parties amended the Agreement effective as of April 1, 2008 to include compensation to
LTS for machine hours; and

WHEREAS, the parties now wish to further amend the Agreement to specify delivery terms and shipment
responsibilities for Clinical Samples.

NOW THEREFORE, in consideration of the premises mutual covenants and conditions set forth herein,
the parties agree as follows:

	 	I.	 	Article II of the Agreement is hereby amended to add the following subsection
2.09:

	 	2.09	 	Clinical Samples Delivery Terms.
	 
	 	 	 	When a shipment of Clinical Samples is ready for delivery, LTS
shall notify NuPathe in writing of the expected delivery date
(including details of quantities, destination, date and time) to
enable delivery and receipt to be coordinated. LTS shall ship the
Clinical Samples to NuPathe ex works (INCOTERMS 2000), LTS
manufacturing facility Andernach, Germany, in accordance with
written shipping instructions provided by NuPathe as per the
Quality Agreement. NuPathe will bear all risk of loss, delay, or
damage in transit, and insurance for each shipment.

	 	II.	 	Capitalized terms used herein and not otherwise defined herein shall have the
meanings set forth in the Agreement.

 

 

	 	III.	 	Except as expressly provided to the contrary in this Amendment No. 2, all
other terms and conditions of the Agreement shall continue in full force and effect.

     IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 2 by their duly
authorized officers as of the date set forth below.

	 	 	 	 	 	 	 	 	 

	LTS LOHMANN Therapie-Systeme AG	 	 	 	NuPathe Inc.
	 
	 	 	 	 	 	 	 	 
	/s/ ppa. K. Haczkiewicz	 	 	 	/s/ Jane H. Hollingsworth
	 	 	 	 	   
	Name:

	 	K. Haczkiewicz
	 	 	 	Name:
	 	Jane H. Hollingsworth
	Title: Head of Business Development
	 	 	 	Title: CEO
	Place, Date: Andernach, March 16, 2009
	 	 	 	Place, Date:
	 
	 	 	 	 	 	 	 	 
	/s/ ppa. U. Sielaff	 	 	 	 	 	 
	 	 	 	 	 	 	 
	Name:

	 	U. Sielaff	 	 	 	 	 	 
	Title: General Counsel	 	 	 	 	 	 
	Place, Date: Andernach, March 16, 2009	 	 	 	 	 	 

 

 

Amendment No 3 to the Development and License Agreement

between LTS LOHMANN Therapie-Systeme AG and Nupathe Inc.

Effective as of Mai 10, 2010

This amendment, effective as of Mai 10, 2010 (“Effective Date”) by and among LTS LOHMANN
Therapie-Systeme AG, a company organized under the laws of Germany having a principal place of
business at Lohmannstrabe 2, 56626 Andernach, Federal Republic of Germany (“LTS”)

and

NuPathe Inc., a corporation organized under the laws of Delaware having a principal place of
business at 227 Washington Street, Suite 200, Conshohocken, PA 19428 (“NuPathe”)

WHEREAS, LTS and NuPathe have concluded a Development and License Agreement effective as of
September 14, 2007 (the “Agreement”); and

WHEREAS, the parties amended the Agreement effective as of April 1, 2008 to include compensation to
LTS for machine hours; and

WHEREAS, the parties amended the Agreement effective as of February 17, 2009 to specify delivery
terms and shipment responsibilities for Clinical Samples; and

WHEREAS, the parties now wish to further amend the Agreement concerning their respective
confidentiality obligations

NOW THEREFORE, in consideration of the premises mutual covenants and conditions set forth herein,
the parties agree as follows:

	 	I.	 	Article X of the Agreement is hereby amended to add the following language:
	 
	 	 	 	“Notwithstanding the foregoing, the following additional disclosures shall be permitted
without obtaining the prior written consent of the other party:

	 
	 	(a)   NuPathe may disclose Confidential Information of LTS Corp. to third parties in
connection with sublicenses, strategic collaborations, equity or debt financing, IPO,
merger, acquisition, changes of control or other similar transactions (“Transactions”),
for the sole purposes of enabling such third parties to conduct such Transactions
and/or any diligence in connection with such Transactions. In the case of Confidential
Information comprising batch records, manufacturing instructions, details of the
manufacturing process, specifications, supply price, quality audit reports and
regulatory filings detailing manufacturing know-how and LTS Corp. patent applications
prior to disclosing such Confidential Information of LTS Corp. to a third party,
NuPathe shall first obtain a written confidentiality agreement with such third party
that is reasonable and customary for such Transaction or diligence.

 

 

	 	(b)	 	Legal Requirements or Governmental Filings. In addition, each Party may use and
disclose Confidential Information of the other Party to the extent such use or
disclosure is necessary in prosecuting or defending litigation in accordance with this
Agreement, complying with applicable governmental laws or regulations, such as FDA or
SEC regulations, or court order or otherwise submitting information to tax or other
governmental authorities, in submissions to regulatory authorities, as a part of patent
applications filed on inventions made under this Agreement, or as a part of
applications for marketing approval; provided that if a Party is required by law to
make any such disclosure, other than pursuant to a confidentiality agreement, it will
give reasonable advance notice to the other Party of such disclosure and, except to the
extent inappropriate in the case of patent applications or the like, will use
reasonable commercial efforts to secure confidential treatment of such information.
Section 4 of the CDA concluded between Nupathe and LTS Lohmann Therapy Systems Corp.
dated May 31st, 2006 shall not apply to information of the parties generated
and exchanged during the performance of activities under this Agreement.”
	 
	 	II.	 	Capitalized terms used herein and not otherwise defined herein shall have the
meanings set forth in the Agreement.
	 
	 	III.	 	Except as expressly provided to the contrary in this Amendment No. 3, all other terms
and conditions of the Agreement shall continue in full force and effect.

                    IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 3 by their duly
authorized officers as of the date set forth below.

	 	 	 	 	 	 	 	 	 

	LTS LOHMANN Therapie-Systeme AG	 	 	 	NuPathe Inc.
	 
	 	 	 	 	 	 	 	 
	/s/ ppa. U. Sielaff	 	 	 	/s/ Suzanne M. Hanlon
	 	 	 	 	 
	Name:

	 	Ulrich Sielaff
	 	 	 	Name:	 	 
	Title: General Counsel
	 	 	 	Title: General Counsel
	Place, Date: Andernach, 10.05.2010
	 	 	 	Place, Date: Conshohocken, May 10, 2010
	 
	 	 	 	 	 	 	 	 
	/s/ ppa. K. Haczkiewicz	 	 	 	 	 	 
	 	 	 	 	 	 	 
	Name:

	 	Klaudia Haczkiewicz	 	 	 	 	 	 
	Title: Head of Business Development	 	 	 	 	 	 
	Place, Date: Andernach, 10.05.2010exv10w3

Exhibit 10.3

Execution Copy

ASSET PURCHASE AND LICENSE AGREEMENT

BY AND BETWEEN

NUPATHE INC.,

AND

TRAVANTI PHARMA INC.

 

 

TABLE OF CONTENTS

	 	 	 	 	 
	 	 	Page
	Article I DEFINITIONS
	 	 	1	 
	 
	 	 	 	 
	Section 1.1 Definitions
	 	 	1	 
	 
	 	 	 	 
	Article II PURCHASE AND SALE
	 	 	6	 
	 
	 	 	 	 
	Section 2.1 Purchase and Sale of Assets
	 	 	6	 
	Section 2.2 Assumed Liabilities
	 	 	6	 
	Section 2.3 Effective Date
	 	 	6	 
	 
	 	 	 	 
	Article III FINANCIAL
	 	 	6	 
	 
	 	 	 	 
	Section 3.1 Purchase Price
	 	 	6	 
	 
	 	 	 	 
	Article IV GRANTS OF LICENSE AND LICENSE TERMS
	 	 	6	 
	 
	 	 	 	 
	Section 4.1 License to NuPathe
	 	 	6	 
	Section 4.2 License to Travanti
	 	 	7	 
	Section 4.3 Other Intellectual Property under the WEDD Technology License
	 	 	7	 
	Section 4.4 Infringement of Patents
	 	 	8	 
	Section 4.5 Third Party Claims
	 	 	8	 
	 
	 	 	 	 
	Article V REPRESENTATIONS AND WARRANTIES OF TRAVANTI
	 	 	9	 
	 
	 	 	 	 
	Section 5.1 Organization; Standing and Power
	 	 	9	 
	Section 5.2 Authority; Binding Agreements
	 	 	9	 
	Section 5.3 Compliance; Conflicts; Governmental Consents
	 	 	9	 
	Section 5.4 Good Title; Sufficiency of Assets
	 	 	10	 
	Section 5.5 Intellectual Property
	 	 	10	 
	Section 5.6 Litigation
	 	 	11	 
	Section 5.7 Adverse Information
	 	 	11	 
	Section 5.8 Taxes
	 	 	11	 
	Section 5.9 Regulatory Matters
	 	 	11	 
	Section 5.10 Adequate Consideration
	 	 	12	 
	Section 5.11 Indemnity By Travanti
	 	 	12	 
	 
	 	 	 	 
	Article VI REPRESENTATIONS, WARRANTIES AND INDEMNITY OF NUPATHE
	 	 	12	 
	 
	 	 	 	 
	Section 6.1 Organization; Standing and Power
	 	 	12	 
	Section 6.2 Authority; Binding Agreements
	 	 	12	 
	Section 6.3 Conflicts; Consents
	 	 	13	 
	Section 6.4 Indemnity By NuPathe
	 	 	13	 
	 
	 	 	 	 
	Article VII ADDITIONAL MATTERS
	 	 	13	 
	 
	 	 	 	 
	Section 7.1 Certain Tax Matters
	 	 	13	 
	Section 7.2 Cooperation in Anti-Migraine Patent Maintenance
	 	 	14	 
	Section 7.3 Expenses
	 	 	14	 
	Section 7.4 Further Assurances
	 	 	14	 

 

 

TABLE OF CONTENTS

	 	 	 	 	 
	 	 	Page
	Article VIII EFFECTIVE DATE DELIVERABLES
	 	 	14	 
	 
	 	 	 	 
	Section 8.1 Deliveries of Travanti
	 	 	14	 
	Section 8.2 Deliveries of NuPathe
	 	 	14	 
	 
	 	 	 	 
	Article IX MISCELLANEOUS
	 	 	15	 
	 
	 	 	 	 
	Section 9.1 Notices
	 	 	15	 
	Section 9.2 Waiver
	 	 	15	 
	Section 9.3 Entire Agreement; Amendment
	 	 	15	 
	Section 9.4 Assignment
	 	 	16	 
	Section 9.5 Severability
	 	 	16	 
	Section 9.6 Section Headings; Construction
	 	 	16	 
	Section 9.7 Governing Law; Consent to Jurisdiction and Venue
	 	 	16	 
	Section 9.8 Counterparts
	 	 	16	 
	Section 9.9 Time of Essence
	 	 	17	 
	Section 9.10 No Third Party Beneficiaries
	 	 	17	 
	Section 9.11 Confidentiality
	 	 	17	 

 

 

EXHIBITS TO ASSET PURCHASE AGREEMENT

	 	 	 

	Exhibit 1

	 	Travanti Patents
	Exhibit 2

	 	Form of Patent Assignment Agreement

 

 

ASSET PURCHASE AND LICENSE AGREEMENT

          Asset Purchase and License Agreement (this “Agreement”), dated as of July 8, 2008, by and
between Travanti Pharma Inc., a Minnesota corporation with a principal place of business at 2520
Pilot Knob Road, Suite 100, Mendota Heights, MN 55120 (“Travanti”), and NuPathe Inc., a Delaware
corporation with a principal place of business at 227 Washington Street, Suite 200, Conshohocken,
PA 19428 (“NuPathe”).

RECITALS

          WHEREAS, subject to the terms and conditions of this Agreement, Travanti desires to transfer
to NuPathe, and NuPathe desires to acquire from Travanti the Purchased Assets;

          WHEREAS, pursuant to this Agreement and that certain Patent Assignment Agreement, dated as of
the date hereof (the “Patent Assignment”), by and between NuPathe and Travanti, Travanti is
assigning the Anti-Migraine Patent to NuPathe;

          WHEREAS, NuPathe upon the Effective Date shall license to Travanti certain rights under the
Anti-Migraine Patent outside the Field;

          WHEREAS,
NuPathe will continue to license the WEDD® Technology from Travanti under the terms
set forth herein, and grant to Travanti a license to utilize certain NuPathe Intellectual Property
outside of the Field; and

          WHEREAS, NuPathe and Travanti intend for this Agreement to supersede the License Agreement and
any amendments thereto;

          NOW, THEREFORE, in consideration of the mutual benefits to be derived from this Agreement and
of the representations, warranties, conditions, agreements and promises contained herein and other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties hereto, intending to be legally bound, hereby agree as follows:

ARTICLE I

DEFINITIONS

     Section 1.1 Definitions. The capitalized terms used in this Agreement have the respective
meanings ascribed to them as follows:

     “Act” shall mean the Federal Food, Drug and Cosmetic Act, as amended from time to time.

     “Action” shall mean any claim, action, suit, arbitration, inquiry, audit, proceeding or
investigation by or before or otherwise involving, any Governmental Authority.

     “Affiliate” shall mean, with references to any Person, any other Person directly or indirectly
controlling, controlled or under common control with such Person, and “control” shall

 

 

mean the power to direct the management and policies of a Person, whether through the
ownership of voting securities, by contract or otherwise.

     “Agreement” shall have the meaning set forth in the preamble hereof.

     “Anti-Migraine Patent” shall mean that certain patent application No. PCT/US07/09000
(WO/2007/120747) entitled “Transdermal Methods and Systems for the Delivery of Anti-migraine
Compounds Related Applications,” filed on April 12, 2007, and all documentation filed in support
thereof, including any priority applications.

     “Applicable Laws” shall mean all laws, treaties, ordinances, judgments, decrees, directives,
injunctions, orders of any court, arbitrator or governmental agency or authority, rules,
regulations interpretations, and authorizations of any international, national, regional, local or
other governmental body, agency, authority, court or Person having jurisdiction over or related to
the registration, manufacture and sale of the Products as may be in effect from time to time.

     “Books and Records” shall mean all books, records, files (including data files) and documents
(including correspondence) and, to the extent not originals, true and complete copies of all files
relating to the filing, prosecution, issuance, maintenance, enforcement or defense of the
Anti-Migraine Patent in all forms, including electronic, in which they are stored or maintained,
and all data and information included or referenced therein, in each case that are licensed, owned
or controlled by or otherwise in the possession of Travanti or any of its Affiliates, as
applicable.

     “Consent” shall mean any consent, authorization, permit, certificate, license or approval of,
exemption by, or filing or registration with, any Governmental Agency or other Person.

     “Control” including its various tenses and derivatives (such as “Controlled” and
“Controlling”) shall mean possession of the right, whether directly or indirectly, and whether by
ownership, license or otherwise, to assign or grant a license, sublicense or other right to or
under the Travanti Intellectual Property or under the NuPathe Intellectual Property, as applicable.

     “Dollars” or “$” shall mean United States dollars.

     “Effective Date” shall have the meaning set forth in Section 2.3.

     “Exploit” or “Exploitation” shall mean to make, have made, import, use, sell, offer for sale,
or otherwise dispose of the Products, including all discovery, research, development, registration,
modification, enhancement, improvement, manufacture, storage, formulation, optimization,
importation, exportation, transportation, distribution, commercialization, promotion and marketing
activities related thereto.

     “FDA” shall mean the Food and Drug Administration in the United States, and any successor
thereto.

     “Field” shall mean the development and commercialization of compounds, drugs and/or medical
devices, including combinations thereof, for acute, chronic and prophylactic treatment, or
prevention, palliation or diagnosis of migraines, including, without limitation, familiar

 

 

hemiplegic migraines, chronic paroxysmal headaches, cluster headaches, migraine headaches
(with and without aura), basilar migraines, and atypical headaches accompanied by autonomic
symptoms, or for any condition defined as a migraine in the International Classification of
Migraine by the International Headache Society.

     “Governmental Authority” shall mean any supra-national, federal, state, local or foreign
government, legislature, governmental or administrative agency, department, commission, bureau,
board, instrumentality, self-regulatory association or authority, court or other authority of
tribunal of competent jurisdiction (including any arbitration or other alternative dispute forum),
or any other governmental authority or instrumentality anywhere in the world.

     “Intellectual Property” shall mean all intellectual property rights, whether registered or
unregistered, including (a) Patents, (b) Trademarks, (c) other intellectual property rights,
including confidential information, trade secrets, and similar proprietary rights in confidential
inventions, discoveries, analytic models, improvements, processes, techniques, devices, methods,
patterns, formulations and specifications, (d) all completed or pending registrations, renewals or
applications for registration or renewal of any of the foregoing, and (e) copies and tangible
embodiments of any of the foregoing (in whatever form or media).

     “License Agreement” shall mean the License Agreement, by and between Travanti and NuPathe,
dated as of July 20, 2005, as amended by the Addendum to the License Agreement, dated as of March
1, 2007.

     “Lien” shall mean any lien (statutory or otherwise), security interest, pledge, hypothecation,
mortgage, assessment, lease, claim, levy, license, defect in title, charge, or any other third
party right, license or property interest of any kind, or any conditional sale or other title
retention agreement, right of first option, right of first refusal or similar restriction, any
covenant not to sue, or any restriction on use, transfer, receipt of income or exercise of any
other attribute of ownership, or any agreement to give any of the foregoing in the future or
similar encumbrance of any kind or nature whatsoever.

     “NDA” shall mean a New Drug Application for any product requesting permission to place the
product on the market in accordance with the Act, together with all supplements or amendments filed
with respect thereto pursuant to the requirements of the Act, including all documents, data and
other information concerning the product that are reasonably necessary for the FDA approval to
market the product in the United States.

     “NuPathe Intellectual Property” shall have the meaning set forth in Section 4.2(b).

     “Order” shall mean any writ, judgment, decree, injunction or similar order, including consent
orders, of any Governmental Authority (in each such case whether preliminary or final).

     “Patents” shall mean (a) all national, regional and international patents and patent applications,
including provisional patent applications; (b) all patent applications filed either from such
patents, patent applications or provisional applications or from an application claiming priority
from either of these, including divisionals, continuations, continuations-in-part, substitutions,
provisionals, converted provisionals, and continued prosecution applications; (c) any and all
patents that have issued or in the future issue from the foregoing patent applications

 

 

described in clauses (a) and (b); (d) any and all extensions or restorations by existing or future
extension or restoration mechanisms, including revalidations, reissues, re-examinations and
extensions (including any supplementary protection certificates and the like) of the foregoing
patents or patent applications described in clauses (a), (b) and (c); and (e) any similar rights,
including so-called pipeline protection, or any importation, revalidation, confirmation or
introduction patent or registration patent or patent of additions to any such foregoing patent
applications and patents.

     “Person” shall mean a person, partnership, firm, enterprise, association, joint venture,
corporation, limited liability company, or any other organization or entity.

     “Products” shall mean any and all pharmaceutical products related to, derived from or
supported by the Anti-Migraine Patent and/or the WEDD® Technology.

     “Purchased Assets” shall mean the Anti-Migraine Patent and all Books and Records related
thereto.

     “Regulatory Approval” shall mean, with respect to a country in the Territory, any and all
approvals, licenses, registrations or authorizations of any Governmental Authority necessary or
useful for the Exploitation of the Products in the Field in such country.

     “Regulatory Documentation” shall mean any and all applications, registrations, licenses,
authorizations and approvals prepared for submission to a Governmental Authority with a view to the
granting of any Regulatory Approval, and any correspondence to or with the FDA or any other
Governmental Authority with respect to the Products in the Field, as applicable, including, for
clarity, original and, if available, electronic copies of all (a) tests and data generated
therefrom, (b) all correspondence and other documentation related to communications to or from
Governmental Authorities, and (c) all other supporting documentation and materials that would be
necessary or useful to obtain or maintain Regulatory Approvals in connection with the Products in
the Field.

     “Related Documents” shall mean, other than this Agreement, the Patent Assignment and all other
agreements, certificates and documents signed and delivered by either party in connection with this
Agreement.

     “Settlement Agreement” shall mean the Settlement Agreement by and between Travanti and
NuPathe, dated as of March 1, 2007.

     “Tax” or “Taxes” shall mean any and all federal, state, local, or foreign net or gross income,
gross receipts, net proceeds, sales, use, ad valorem, value added, franchise, bank shares,
withholding, payroll, employment, excise, property, deed, stamp, alternative or add-on minimum,
environmental, profits, windfall profits, transaction, license, lease, service, service use,
occupation, severance, energy, unemployment, social security, workers’ compensation, capital,
premium, and other taxes, assessments, customs, duties, fees, levies, or other governmental charges
of any nature whatsoever, whether disputed or not, together with any interest, penalties, additions
to tax, or additional amounts with respect thereto and including any liability for the payment of
the foregoing obligations of another Person as a result of (a) being or

 

having been a member of an affiliated, consolidated, combined, unitary or aggregate group of
corporations; (b) being or having been a party to any tax sharing agreement or any express or
implied obligation to indemnify any Person; and (c) being or having been a transferee,
successor, or otherwise assuming the obligations of another Person to pay the foregoing amounts.

     “Tax Returns” shall mean any return, declaration, report, claim for refund, or information
return or statement relating to Taxes, including any schedule or attachment thereto, and including
any amendment thereof.

     “Territory” shall mean each country throughout the world.

     “Trademark” shall mean (a) any word, name, symbol, color, designation or device or any
combination thereof, including any trademark, trade dress, brand mark, trade name, brand name, logo
or business symbol, (b) all registrations and applications for any of the foregoing, and (c) all
rights and priorities connected with the foregoing afforded under Applicable Law.

     “Travanti Intellectual Property” shall have the meaning set forth in Section 5.5(b).

     “Travanti Know-How” shall mean any and all information and any materials in existence as of
the date of this Agreement, including, without limitation, inventions, formulations, processes,
techniques, formulas, biological, chemical, assay control and manufacturing data, methods,
software, equipment designs, know-how, and trade secrets, patentable or otherwise, tangible or
intangible, that are Controlled by Travanti, and that: (i) arise from practicing art described by
Travanti Patents or the Anti-Migraine Patent; and (ii) are necessary or useful in the development,
commercialization, manufacture, use, sale or import of Products in the Field, or any improvements
thereto in existence on the date hereof (to the extent that such information and inventions are not
generally known).

     “Travanti’s Knowledge” (and similar phrases) shall mean the actual knowledge of any officer,
director, patent attorney or employee of Travanti having primary responsibility for such matter,
without independent investigation or inquiry.

     “Travanti Patents” shall mean any currently existing or future Patents Controlled by Travanti
necessary or required to develop make, have made, use, sell, offer to sell or import the Products
in the Field, including but not limited to, the Patents set forth on Exhibit 1 attached
hereto and the WEDD Technology, and any and all continuations, continuations-in-part, additions,
divisions, renewals, extensions, re-examinations and reissues thereof and any and all foreign
counterparts of the foregoing.

     “Valid Claim” shall mean a claim of an issued and unexpired Patent which can be reasonably
asserted against a party manufacturing, using, offering for sale, selling or importing a Product
absent a license and whose validity or enforceability has not been adversely affected by any of the
following: (i) lapse, revocation, or abandonment, (ii) a determination by a court or other
Governmental Agency of competent jurisdiction, which is unappealable or has not been appealed
within the time allowed for appeal, that the patent is unenforceable or invalid, and/or (iii) a
disclaimer or admission of invalidity or unenforceability through reissue, re-examination,
opposition, nullity action or invalidation suit response, disclaimer or otherwise.

 

 

     “WEDD® Technology” shall mean that wearable electronic disposable drug delivery technology,
covered by a Valid Claim under Travanti Patents existing as of the Effective Date.

ARTICLE II

PURCHASE AND SALE

     Section 2.1 Purchase and Sale of Assets. Pursuant to the terms and subject to the conditions
of this Agreement, in consideration for the entering into the Patent Assignment and the payment of
the fees set forth in the Patent Assignment, Travanti hereby sells, conveys, delivers, transfers
and assigns to NuPathe, free and clear of all Liens, all of Travanti’s (and, as applicable, its
Affiliates’) right, title and interest in, to and under the Purchased Assets (and, as applicable,
its Affiliates).

     Section 2.2 Assumed Liabilities. NuPathe expressly does not assume and shall not become
liable to pay, perform or discharge, any liability, obligation or commitment whatsoever of Travanti
relating to the Purchased Assets.

     Section 2.3 Effective Date. Pursuant to the terms and subject to the conditions of this
Agreement, the signing and closing of the transaction contemplated by this Agreement shall take
place at the offices of Morgan, Lewis & Bockius LLP, 502 Carnegie Center, Princeton, New Jersey, at
10:00 a.m. local time on the date hereof, or such time and place on which the parties agree (the
“Effective Date”).

ARTICLE III

FINANCIAL

     Section 3.1 Purchase Price. Subject to the terms and conditions set forth herein and in the
Patent Assignment, in consideration of the sale, assignment and delivery of the Purchased Assets,
NuPathe shall pay to Travanti the sum of Five Million Five Hundred Thousand Dollars ($5,500,000)
(the “Purchase Price”) on the Effective Date by wire transfer in immediately available funds in
accordance with Travanti’s instructions.

ARTICLE IV

GRANTS OF LICENSE AND LICENSE TERMS

     Section 4.1 License to NuPathe.

     (a) WEDD® Technology. Subject to the terms and conditions contained in this Agreement,
Travanti grants to NuPathe a sole and exclusive, even as to Travanti, perpetual, worldwide,
royalty-free license, with right to grant sublicenses, under Travanti Patents and Travanti
Know-How, to develop, make, have made, use, offer to sell, sell, have sold and import Products in
the Field in the Territory. NuPathe shall not sell Products under the WEDD® Technology outside the
Field.

     (b) Sublicensing. NuPathe acknowledges that the grant of a sublicense under this Section 4.1
shall not relieve NuPathe from its obligations under this Agreement, and NuPathe shall be fully
responsible for the compliance of its sublicensees with the terms and conditions of this
Agreement.

 

 

     Section 4.2 License to Travanti.

     (a) Anti-Migraine Patent for Use Outside the Field. Subject to the terms and conditions
contained in this Agreement, NuPathe grants to Travanti a perpetual, non-exclusive, worldwide,
royalty-free license, with right to grant sublicenses, under the Anti-Migraine Patent, to develop,
make, have made, use, offer to sell, sell, have sold, and import Products outside the Field in the
Territory.

     (b) WEDD® Technology. Subject to the terms and conditions contained in this Agreement,
NuPathe grants to Travanti a perpetual, non-exclusive, worldwide, royalty free license under
NuPathe Intellectual Property to develop, make, have made, use, offer to sell, sell, have sold, and
import Products using or based on the WEDD® Technology outside the Field. “NuPathe Intellectual
Property” shall mean any present or future improvements claimed in a Patent to WEDD® Technology
(i.e., to the extent that practicing such improvements without a license would infringe a Travanti
Patent), which are Controlled by NuPathe.

     (c) No Sales of Products in the Field. Travanti shall not sell Products under the
Anti-Migraine Patent or the WEDD® Technology in the Field.

     (d) Sublicensing. Travanti acknowledges that the grant of a sublicense under this Section 4.2
shall not relieve Travanti from its obligations under this Agreement, and Travanti shall be fully
responsible for the compliance of its sublicensees with the terms and conditions of this Agreement.

	 	 	Section 4.3 Other Intellectual Property under the WEDD® Technology License.

     (a) Trademarks. NuPathe will have the right, in its sole discretion and at its
expense, to select and register those Trademarks it wishes to employ in connection with the sale of
the Products throughout the Territory, and NuPathe will have legal and equitable ownership of the
entire right, title and interest in and to the Trademarks and registrations NuPathe elects to use;
provided, however, that NuPathe shall not use Travanti’s name nor any of Travanti’s Trademarks
without prior written consent, except that NuPathe may state that it is licensed by Travanti under
one or more of the Travanti Patents as authorized by this Agreement or as required by Applicable
Laws.

     (b) Ownership of Data. Each party will own all information and results related to
such party’s own research and development activities for Products it develops, manufactures or
sells in accordance with the terms and conditions of this Agreement, including, without limitation,
any and all research data, pharmacology data, preclinical data, clinical data, and information,
obtained or generated and documentation submitted, or required to be submitted, in association with
regulatory filings for such Products (including any Drug Master Files, Chemistry, Manufacturing and
Control data, or similar documentation).

     (c) Ownership of Regulatory Filings. All INDs, NDAs and other regulatory filings made
or filed by NuPathe with respect to any Products in the Field will be in the name of, and be owned
solely by, NuPathe or its third party licensee, at the discretion of NuPathe.

 

     (d) Patent Prosecution. NuPathe will be responsible, at its own cost, for preparing,
prosecuting and maintaining the NuPathe Intellectual Property and the Anti-Migraine Patent.
Travanti shall, at its own cost, prepare, prosecute and maintain Travanti Patents during the
term of this Agreement

     (e) Abandonment. In the event Travanti wishes to abandon any Travanti Patents,
Travanti will offer to assign, free of charge, any such Patent or Patents to NuPathe prior to
effectuating the abandonment. Should NuPathe elect to become an assignee of such Patents, NuPathe
will bear the costs connected to any assignment hereunder.

     Section 4.4 Infringement of Patents. If either party has knowledge of any infringement of the
Travanti Know-How or Travanti Patents that could negatively impact either party’s exercise of the
license rights granted under Article 4 of this Agreement, the party having such knowledge shall
promptly inform the other of such infringement. The parties will thereafter discuss what action
should be taken, including whether any legal proceeding should be instituted. If the parties
mutually agree on the course of action to be taken in respect of any such infringement, they will
jointly select counsel and equally share any expenses. Any settlement or recovery shall be
distributed in the following order: (i) pro rata to each party for reimbursement of expenses
related to such claim, including but not limited to attorneys’ fees and expenses associated with
the legal proceedings; (ii) to the licensee of such Intellectual Property for any damages related
to the license rights granted to such party; and (iii) to the extent any settlement or recovery
remains, to each party equally. If either party determines to take action, but the other party
does not desire to do so, the first party may take action at its own expense and through counsel of
its own choice, and any settlement or recovery will in such case belong solely to the party taking
action. If one party institutes and carries on a legal proceeding to enforce Travanti Patents
against an alleged infringing party, the other party will fully cooperate with and supply all
assistance reasonably requested by the party instituting and carrying on such proceeding; provided,
however, that no settlement or consent judgment or other voluntary final disposition of any such
action may be entered into without the written consent of the other party if such settlement would
require the other party to be subject to an injunction or to make a monetary payment or would
restrict the claims in or admit any invalidity of any Intellectual Property Rights or otherwise
adversely affect the rights of the other party to this Agreement.

	 	 	Section 4.5 Third Party Claims.

          (i) Notice. In the event that a party becomes aware of any claim filed with a
Governmental Authority that the performance of this Agreement infringes the intellectual property
rights of a third party, such party will promptly notify the other party.

          (ii) Third Party License. If NuPathe would be prevented from using, selling or
importing Product in any country of the Territory on grounds that by doing so NuPathe would
infringe a Valid Claim of a Patent held by a third party in said country (the “Blocking Third Party
IP”), NuPathe will notify Travanti and give Travanti a reasonable opportunity to oppose or
otherwise resolve such claim. In the event that Travanti elects not to oppose the claim or does
not successfully obtain any necessary license, NuPathe will have the right to negotiate directly
with such third party for a license under the Blocking Third Party IP.

 

 

ARTICLE V

REPRESENTATIONS AND WARRANTIES OF TRAVANTI

     Travanti represents and warrants to NuPathe, as of the Effective Date, as follows, with each
such representation and warranty subject only to such exceptions, if any, as are set forth in the
particular disclosure schedule numbered and captioned to correspond to, and referenced in, such
representation or warranty:

     Section 5.1 Organization, Standing and Power. Travanti is a corporation duly organized,
validly existing and in good standing under the laws of the Minnesota. Travanti is duly qualified
to do business and is in good standing in each jurisdiction in which such qualification is
necessary.

     Section 5.2 Authority; Binding Agreements. The execution and delivery by Travanti of this
Agreement and the Related Documents to which it is or will become a party and the consummation of
the transaction contemplated hereby have been duly and validly authorized by all necessary action
on the part of Travanti. Travanti has all requisite power and authority to enter into this
Agreement and the Related Documents to which it is or will become a party and to consummate the
transaction contemplated hereby, and this Agreement and such Related Documents have been, or upon
execution and delivery thereof will be, duly executed and delivered by Travanti. No shareholder or
other equity holder approval is required on behalf of Travanti for the execution, delivery or
performance of this Agreement and such Related Documents. This Agreement and the Related Documents
to which Travanti is or will become a party are, or upon execution and delivery by Travanti thereof
will be, the valid and binding obligations of Travanti, enforceable against Travanti in accordance
with their respective terms.

     Section 5.3 Compliance; Conflicts; Governmental Consents. The execution and delivery by
Travanti of this Agreement and the Related Documents to which it is or will become a party, the
consummation of the transaction contemplated hereby and compliance by Travanti with any of the
provisions hereof and thereof do not and will not:

     (a) conflict with or result in a breach of the certificate of incorporation, bylaws or other
constitutive or organizational documents of Travanti;

     (b) violate any Applicable Law with respect to Travanti or the Purchased Assets;

     (c) result in the creation or imposition of any Lien upon the Purchased Assets; or

     (d) require any material notice to, filing with, authorization of, exemption by, or Consent
of, any Person, including any Governmental Authority, including any foreign Governmental Authority,
for Travanti to transfer the Purchased Assets to NuPathe and otherwise consummate the transaction
contemplated hereunder.

     Section 5.4 Good Title; Sufficiency of Assets. Travanti (i) has good and marketable title to
the Purchased Assets free and clear of all Liens, and has the complete and unrestricted power and
unqualified right to sell, convey, deliver, transfer and assign to NuPathe, as applicable, the
Purchased Assets; and (ii) to Travanti’s Knowledge, there are no adverse claims of ownership to the
Purchased Assets and Travanti has not received notice that any Person has

 

 

asserted a claim of ownership or right of possession or use in or to any of the Purchased
Assets. On the Effective Date, NuPathe will acquire from Travanti, good and marketable title to
the Purchased Assets, free and clear of all Liens.

     Section 5.5 Intellectual Property.

     (a) Travanti owns all right, title and interest in and to, and has the unrestricted right to
assign to NuPathe, all right, title and interest in, to and under the Purchased Assets, in each
case to Travanti’s Knowledge free of any rights or claims of any Person or any other Liens, and
without payment by either party of any royalties, license fees or other amounts to any other
Person.

     (b) Travanti has valid rights to grant the license rights to the Travanti Intellectual
Property to NuPathe as provided herein. The “Travanti Intellectual Property” means the Travanti
Patents and/or other Intellectual Property Controlled by, or otherwise in the possession of,
Travanti that is necessary for NuPathe to Exploit the Anti-Migraine Patent and the Products as
authorized herein.

     (c) Travanti Intellectual Property is, to Travanti’s Knowledge, enforceable and valid, and
Travanti has not received any notice that Travanti Intellectual Property has been or is the subject
of (A) any pending Action (including, with respect to the Patents included in the Travanti
Intellectual Property, inventorship challenges, interferences, reissues, reexaminations and
oppositions or similar Actions) or any Order or other agreement restricting (x) the use of any
Travanti Intellectual Property in connection with the Exploitation of any Product in the Field or
(y) the assignment or license thereof by Travanti (or any of its Affiliates, as applicable), or (B)
any threatened Action or claim of infringement threatened or made in writing or any pending Action
to which Travanti (or any of its Affiliates, as applicable) is a party.

     (d) Neither Travanti nor its Affiliates, if applicable, has entered into any contract (A)
granting any Person the right to bring infringement actions with respect to, or otherwise to
enforce rights with respect to, any of Travanti Intellectual Property in the Field in the
Territory, (B) expressly agreeing to indemnify any Person against any charge of infringement of any
of Travanti Intellectual Property in the Field in the Territory, or (C) granting any Person the
right to control the prosecution of any of Travanti Intellectual Property.

     (e) Travanti has not received notice that there is any unauthorized use, infringement,
misappropriation or violation of any of Travanti Intellectual Property by any Person within the
Territory.

     (f) All issuance, renewal, maintenance and other material payments that are or have become due
with respect to Travanti Intellectual Property have been timely paid by or on behalf of Travanti.
All documents, certificates and other material in connection with such Travanti Intellectual
Property have, for the purposes of maintaining such Travanti Intellectual Property, been filed in a
timely manner with the relevant Governmental Authorities.

     Section 5.6 Litigation. There is no Action pending, or to Travanti’s Knowledge, threatened
before any Governmental Authority, and there is no claim, investigation or administrative action of
any Governmental Authority pending, or to Travanti’s Knowledge,

 

 

threatened, that affects Travanti or the Purchased Assets or that could reasonably be expected
to result in restraining, enjoining or otherwise preventing the completion by Travanti of the
transaction contemplated by this Agreement, nor, to Travanti’s Knowledge, is there any reasonable
basis on which any Action may be brought in the future. There is no outstanding Order of any
Governmental Authority against Travanti relating to the Purchased Assets.

     Section 5.7 Adverse Information. Travanti has not received any notice of any scientific or
technical facts or circumstances that would adversely affect the scientific, therapeutic or
commercial potential of the Anti-Migraine Patent.

     Section 5.8 Taxes.

     (a) Travanti (and each of its Affiliates, as applicable) has timely paid all Taxes that will
have been required to be paid by it, the non-payment of which would result in a Lien on the
Purchased Assets or would result in NuPathe becoming liable or responsible therefor.

     (b) Travanti (and each of its Affiliates, as applicable) has established, in accordance with
generally accepted accounting principles, as applied in the United States, applied on a basis
consistent with that of preceding periods, adequate reserves for the payment of, and will timely
pay, all Taxes that arise from or with respect to the Purchased Assets, the non-payment of which
would result in a Lien on the Purchased Assets or would result in NuPathe becoming liable therefor.

     Section 5.9 Regulatory Matters.

     (a) Neither Travanti nor any of the employees of Travanti that conducted any activities or
services relating to the Purchased Assets and/or Products has been disqualified, debarred or
voluntarily excluded by the FDA or any other Governmental Authority for any purpose, or has been
charged with or convicted under United States federal law for conduct relating to the development
or approval, or otherwise relating to the regulation, of any drug product under the Generic Drug
Enforcement Act of 1992, the Act or any other Applicable Law, or, to Travanti’s Knowledge, has made
an untrue statement of a material fact to any Governmental Authority with respect to the Purchased
Assets (whether in any submission to such Governmental Authority or otherwise), or failed to
disclose a material fact required to be disclosed to any Governmental Authority with respect to the
Purchased Assets. Neither Travanti nor any employee of Travanti has received any notice to such
effect.

     (b) Travanti has made available, or has caused its Affiliates to make available, to NuPathe
all Regulatory Documentation, Travanti Know-How and any other data and information and inventions
in Travanti’s or Travanti’s Affiliates’ possession or Control as of the Effective Date regarding or
related to the Anti-Migraine Patent. To Travanti’s Knowledge, Travanti has prepared, maintained
and retained all Regulatory Documentation that is required to be maintained or reported pursuant to
and in accordance with good laboratory and clinical practices and other Applicable Laws.

     (c) Travanti and its Affiliates have assigned to NuPathe all of Travanti and its Affiliates’
right, title and interest in and to all Regulatory Documentation, including, to the extent
permitted by Applicable Law, all applicable Regulatory Approvals Controlled by Travanti

 

 

or its Affiliates at any time prior to the Effective Date. Travanti has executed and
delivered, or caused to be executed and delivered, all such instruments and has done and caused to
be done all such acts and things, including the filing of such assignments, agreements, documents
and instruments, as were necessary under, or as NuPathe has reasonably requested in connection
with, or to carry out more effectively the purpose of, or to better assure and confirm unto NuPathe
its rights with respect to the Purchased Assets with respect to the Regulatory Documentation.

     Section 5.10 Adequate Consideration. The consideration to be received by Travanti under the
Patent Assignment constitutes fair consideration and reasonable value for the Purchased Assets and
the WEDD® Technology license.

     Section 5.11 Indemnity By Travanti. Travanti will indemnify and hold NuPathe, its directors,
officers, employees and agents harmless against any and all liability, damage, loss, cost or
expense (including reasonable attorney’s fees) resulting from any third party claims made or suits
brought against NuPathe which arise from an act or failure to act by Travanti or Travanti’s breach
of any of its representations, warranties or agreements contained herein.

ARTICLE VI

REPRESENTATIONS, WARRANTIES AND INDEMNITY OF NUPATHE

     NuPathe represents and warrants to Travanti, as of the Effective Date, as follows, with each
such representation and warranty subject only to such exceptions, if any, as are set forth in the
particular disclosure schedule numbered and captioned to correspond to, and referenced in, such
representation or warranty:

     Section 6.1 Organization, Standing and Power. NuPathe is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware and has all requisite
power and authority to carry on its business as now being conducted.

     Section 6.2 Authority; Binding Agreements. The execution and delivery by NuPathe of this
Agreement and the Related Documents to which it is or will become a party and the consummation of
the transaction contemplated hereby have been duly and validly authorized by all necessary action
on the part of NuPathe. NuPathe has all requisite power and authority to enter into this Agreement
and the Related Documents to which it is or will become a party and to consummate the transaction
contemplated hereby, and this Agreement and such Related Documents have been, or upon execution and
delivery thereof will be, duly executed and delivered by NuPathe. This Agreement and the Related
Documents to which NuPathe is or will become a party are, or upon execution and delivery thereof
will be, the valid and binding obligations of NuPathe, enforceable against NuPathe in accordance
with their respective terms.

     Section 6.3 Conflicts; Consents. The execution and delivery by NuPathe of this Agreement and
the Related Documents to which it is or will become a party, the consummation of the transaction
contemplated hereby and compliance by NuPathe with the provisions hereof and thereof do not and
will not (a) conflict with or result in a breach of the constitutive or organizational documents of
NuPathe, or (b) violate any Applicable Law with respect to NuPathe or NuPathe’s properties or
assets.

 

 

     Section 6.4 Indemnity By NuPathe. NuPathe will indemnify and hold Travanti, its directors,
officers, employees and agents harmless against any and all liability, damage, loss, cost or
expense (including reasonable attorney’s fees) resulting from any third party claims made or suits
brought against Travanti arising from an act or failure to act by NuPathe, or NuPathe’s breach of
any of its representations, warranties or agreements contained herein.

ARTICLE VII

ADDITIONAL MATTERS

     Section 7.1 Certain Tax Matters.

     (a) Waiver of Bulk Sales. NuPathe hereby waives compliance by Travanti with the requirements
and provisions of any “bulk-transfer” laws of any jurisdiction (including applicable Tax laws) that
may otherwise be applicable with respect to the sale of any or all of the Purchased Assets to
NuPathe (including the requirement to withhold any amount from payment of the Purchase Price);
provided, however, that Travanti shall pay and discharge when due all claims of creditors asserted
against NuPathe or the Purchased Assets by reason of such noncompliance and shall take promptly all
necessary actions required to remove any encumbrance which may be placed upon any of the Purchased
Assets by reason of such noncompliance and otherwise indemnify NuPathe against any losses it
suffers as a result of such non-compliance.

     (b) Cooperation and Exchange of Information. Each of Travanti and NuPathe shall (i) provide
the other with such assistance as may reasonably be requested by the other party in connection with
the preparation of any Tax Return, audit or other examination by any taxing authority or Action
relating to liability for Taxes in connection with the Purchased Assets, (ii) retain and provide
the other with any records or other information that may be relevant to such Tax Return, audit or
examination, Action or determination, and (iii) provide the other with any final determination of
any such audit or examination, Action or determination that affects any amount required to be shown
on any Tax Return of the other for any period.

     (c) Survival of Covenants. The covenants contained in this Section 7.1 shall survive until
thirty (30) days after the expiration of the applicable statute of limitations (including
extensions thereof).

     (d) Indemnification. In addition to the indemnification provided for in Section 7.1(a),
Travanti shall indemnify and hold NuPathe harmless for: (i) any Taxes of Travanti and any Taxes
associated with the Purchased Assets as of the date hereof; and (ii) the breach of any of
Travanti’s representations set forth in Section 5.8. Any transfer taxes associated with the
transfer of the Purchased Assets (including any periodic taxes associated with the Purchased Assets
for 2008) shall be apportioned between Travanti and NuPathe on a daily proration basis.

     Section 7.2 Cooperation in Anti-Migraine Patent Maintenance. From and after the Effective
Date, Travanti shall cooperate and assist NuPathe, at NuPathe’s cost and expense, with the filing,
prosecution, defense and enforcement of the Anti-Migraine Patent, including by providing access to
inventors and other persons familiar with the conception and reduction to practice of any
information and inventions related to the Anti-Migraine Patent.

 

 

     Section 7.3 Expenses. Except as expressly set forth herein, each of Travanti and NuPathe
shall bear its own costs and expenses incurred in connection with this Agreement.

     Section 7.4 Further Assurances. Travanti shall, and shall cause its Affiliates to, at any
time and from time to time after the Effective Date, upon the request and at the cost and expense
of NuPathe, do, execute, acknowledge, deliver and file, or cause to be done, executed,
acknowledged, delivered and filed, all such further acts, deeds, transfers, conveyances,
assignments or assurances as may be reasonably required for the better transferring, conveying,
assigning and assuring to NuPathe, or for the aiding and assisting in the reducing to possession by
NuPathe of, any of the Purchased Assets, or for otherwise carrying out the purposes of this
Agreement and the Related Documents and the consummation of the transaction contemplated hereby.

ARTICLE VIII

EFFECTIVE DATE DELIVERABLES

     Section 8.1 Deliveries of Travanti. On the Effective Date, Travanti shall deliver, or caused
to be delivered to NuPathe:

     (a) a Patent Assignment, substantially in the form of Exhibit 2, as may be necessary,
among other things, to effect the assignment to NuPathe of all rights of Travanti (and its
Affiliates, as applicable) in and to the Anti-Migraine Patent, duly executed by Travanti (or its
Affiliates, as applicable);

     (b) a properly completed IRS form W-9 duly executed by Travanti; and

     (c) such other documents, certifications and further assurances as NuPathe may reasonably
request in order to vest more effectively in NuPathe, or to put NuPathe more fully in possession
of, the Purchased Assets and any rights granted by Travanti to NuPathe under Travanti Patents and
Travanti Know How.

     Section 8.2 Deliveries of NuPathe. Except as otherwise provided for in this Agreement, on the
Effective Date, NuPathe shall deliver, or caused to be delivered to Travanti:

     (a) the Purchase Price pursuant to Section 3.1;

     (b) the Patent Assignment duly executed by NuPathe; and

     (c) such other documents, certifications and further assurances as Travanti may reasonably
request in order to vest more effectively in Travanti, or to put Travanti more fully in possession
of, any rights granted by NuPathe to Travanti under the NuPathe Intellectual Property.

ARTICLE IX

MISCELLANEOUS

     Section 9.1 Notices. All notices, consents, waivers and other communications under this
Agreement must be in writing and shall be deemed to have been duly given when: (a)

 

 

delivered by hand (with written confirmation of receipt), or (b) when received by the
addressee, if sent by a delivery service (prepaid, receipt requested), or (c) when received by the
addressee, if sent by registered or certified mail (postage prepaid, return receipt requested), in
each case to the appropriate addresses set forth below (or to such other addresses, representative
and telecopier numbers as a party may designate by notice to the other parties):

     If to Travanti, to:

Travanti Pharma, Inc.

2520 Pilot Knob Road (Suite 100)

Mendota Heights, MN 55120

Attn: Chief Executive Officer

Facsimile: 651-730-1013

If to NuPathe, to:

NuPathe, Inc.

227 Washington Street, Suite 200

Conshohocken, PA 19428

Attn: General Counsel

Facsimile: 484-567-0136

     Section 9.2 Waiver. Except as explicitly provided in this Agreement, the rights and remedies
of the parties under this Agreement are cumulative and not alternative and are not exclusive of any
right or remedies that any party may otherwise have at law or in equity. Except as explicitly
provided in this Agreement, neither the failure nor any delay by any party in exercising any right,
power, or privilege under this Agreement or the documents referred to in this Agreement shall
operate as a waiver of such right, power or privilege, and no single or partial exercise of any
such right, power, or privilege shall preclude any other or further exercise of such right, power,
or privilege or the exercise of any other right, power, or privilege. To the maximum extent
permitted by Applicable Law, (a) no waiver that may be given by a party shall be applicable except
in the specific instance for which it is given, and (b) no notice to or demand on one party shall
be deemed to be a waiver of any right of the party giving such notice or demand to take further
action without notice or demand.

     Section 9.3 Entire Agreement; Amendment. This Agreement and the Related Documents, together
with the Settlement Agreement, supersede all prior agreements between the parties with respect to
its subject matter and constitute a complete and exclusive statement of the terms of the agreements
between the parties with respect to their subject matter. This Agreement may not be amended except
by a written agreement executed by all of the parties hereto.

     Section 9.4 Assignment. Neither this Agreement nor any interest herein may be assigned, in
whole or in part, by either party hereto without the prior written consent of the other party
hereto, provided, that either party shall have the right to assign all or any part of its rights,
interest and obligations to an Affiliate, a successor to a controlling or majority share of such
party, or to a successor to substantially all the business to which this Agreement relates.
Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the
parties hereto and their respective permitted successors and assigns.

 

 

     Section 9.5 Severability. If any term or other provision of this Agreement is invalid,
illegal or incapable of being enforced by any requirement of applicable law or public policy, all
other conditions and provisions of this Agreement shall nevertheless remain in full force and
effect so long as the economic or legal substance of the transactions contemplated hereby is not
affected in any manner adverse to any party in any material respect. Upon such determination that
any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto
shall negotiate in good faith to modify this Agreement so as to effect the original intent of the
parties as closely as possible in a mutually acceptable manner in order that the transactions
contemplated hereby be consummated as originally contemplated to the greatest extent possible.

     Section 9.6 Section Headings; Construction. The headings of Sections in this Agreement are
provided for convenience only and shall not affect its construction or interpretation. All
references to “Article,” “Section” or “Sections” refer to the corresponding Article, Section or
Sections of this Agreement. All words used in this Agreement shall be construed to be of such
gender or number as the circumstances require. Unless otherwise expressly provided, the word
“including” does not limit the preceding words or terms.

     Section 9.7 Governing Law; Consent to Jurisdiction and Venue.

     (a) This Agreement shall be governed by, and construed in accordance with, the laws of the
State of Delaware applicable to contracts executed in and to be performed in that State, without
giving effect to the conflicts of laws principles thereof to the extent such principles would
require or permit the application of the laws of another state.

     (b) All actions and proceedings arising out of or relating to this Agreement shall be heard
and determined in a Delaware state or a federal court and the parties to this Agreement hereby
irrevocably submit to the exclusive jurisdiction of such courts in any such action or proceeding
and irrevocably waive the defense of an inconvenient forum to the maintenance of any such action or
proceeding. The parties hereto hereby consent to service of process by mail (in accordance with
Section 9.1 or any other manner permitted by law).

     Section 9.8 Counterparts. This Agreement may be executed in one or more counterparts, each of
which shall be deemed to be an original of this Agreement and all of which, when taken together,
shall be deemed to constitute one and the same agreement. Delivery of an executed counterpart of a
signature page to this Agreement by electronic or facsimile transmission shall be effective as
delivery of a manually executed counterpart of this Agreement.

     Section 9.9 Time of Essence. Time is of the essence in this Agreement.

     Section 9.10 No Third Party Beneficiaries. This Agreement is for the sole benefit of the
parties hereto and nothing herein, express or implied, is intended to or shall confer upon any
other Person any legal or equitable benefit, claim, cause of action, remedy or right of any kind.

     Section 9.11 Confidentiality.

     (a) Any and all information provided by one party to the other pursuant to this Agreement
shall be deemed to be confidential information (“Confidential Information”). Each party will hold
Confidential Information in complete confidence and will not, with the prior

 

 

written consent of the other, use or disclose it in whole or in part to any person other than
for the purposes set forth in this Agreement for a period ending five (5) years following
expiration of this Agreement. Each party will be entitled to disclose any such Confidential
Information to such of its provisional advisors, directors, officers and senior employees who are
directly concerned with this Agreement and its implementation and whose knowledge of such
information is necessary for these purposes. Each party will use its reasonable efforts to ensure
that each individual to whom such a disclosure is made adheres to the terms of this undertaking as
if he or she were a party hereto, including without limitation, having such individuals execute
similar agreements.

     (b) As used herein, the term Confidential Information shall not include information:

          (i) that the recipient can demonstrate through its contemporaneous written records has become
generally available to third parties after disclosure to the recipient from a source other than the
discloser; provided that such source is not bound by a confidentiality or other similar agreement
with the discloser or by any other legal, contractual or fiduciary obligation which prohibits the
disclosure of such Confidential Information;

          (ii) was lawfully in possession of the recipient prior to disclosure, as evidenced by written
records and which was not acquired directly or indirectly from the disclosing party; or

          (iii) which the recipient is required by legal process, law or regulation to disclose or,
after consultation with legal counsel, determines it prudent to be disclosed to the extent required
under the laws, guidelines, or regulations or pursuant to any request by an governmental agency
lawfully requesting the same, or to any court of competent jurisdiction acting pursuant to it
lawful powers.

     (c) In the event that a party intends to disclose any Confidential Information pursuant to
Section 9.11 (b)(iii) hereof, such party first shall provide the disclosing with prompt written
notice as far in advance of the proposed disclosure as possible so that the disclosing party (at
its expense) may either seek a protective order or other appropriate remedy which is necessary to
protect its interests or waive compliance with the non-disclosure provisions of this Agreement to
the extent necessary (provided that one or the other be done). The receiving party shall cooperate
in all reasonable respects with the disclosing party in seeking to prevent or limit disclosure and,
in the event a protective order or other remedy is not obtained, will limit the disclosure to the
information actually required to be disclosed.

 

 

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first
above written.

	 	 	 	 	 
	 	NUPATHE INC.

 	 
	 	By:  	/s/  Jane H. Hollingsworth
 	 
	 	 	Name:  	J. Hollingsworth 	 
	 	 	Title:  	CEO 	 
	 
	 	TRAVANTI PHARMA INC.

 	 
	 	By:  	/s/ Robert Cohen
 	 
	 	 	Name:  	Robert Cohen 	 
	 	 	Title:  	[ILLEGIBLE] 	 
	 

 

EXHIBIT 1

Travanti Patents

     Any of the following Patents necessary or required to develop, make, have made, use, sell,
offer to sell or import Products in the Field:

	 	 	 	 	 	 	 
	File No.	 	Title	 	Filing Date	 	Status
	I. ISSUED U.S. PATENTS (6)

	 
	 	 	 	 	 	 
	990322.CIP

	 	CONTROLLED DOSAGE DRUG
	 	CIP-June 10, 2002
	 	UPSN 7,031,768; issued
	 

	 	DELIVERY SYSTEM
	 	 	 	April 18, 2006
	 
	 	 	 	 	 	 
	 

	 	 	 	PRO-December 30, 1999	 	 
	20000315.ORI

	 	RATE ADJUSTABLE DRUG
	 	ORI-July 11, 2000
	 	USPN 6,421,561; issued
	 

	 	DELIVERY SYSTEM
	 	 	 	July 16, 2002
	 

	 	(plural power source + component)	 	 	 	 
	 
	 	 	 	 	 	 
	20000315.CIP

	 	RATE ADJUSTABLE DRUG
	 	June 3, 2002
	 	UPSN 7,016,723; issued
	 

	 	DELIVERY SYSTEM
	 	 	 	March 21, 2006
	 

	 	(includes dosage capacity based on tested lots)	 	 	 	 
	 
	 	 	 	 	 	 
	20010197.ORI

	 	POWER SOURCES FOR
	 	 	 	USPN 6,653,014; issued
	 

	 	IONTOPHORETIC DRUG DELIVERY
	 	May 30, 2001
	 	November 25, 2003
	 

	 	SYSTEMS	 	 	 	 
	 
	 	 	 	 	 	 
	20020208.ORI

	 	DOSAGE CONTROL ELECTRODE
	 	February 21, 2003
	 	USPN 7,031,769; issued
	 

	 	FOR IONTOPHORESIS DEVICE
	 	 	 	April 18, 2006
	 
	 	 	 	 	 	 
	20030061.ORI

	 	IONTOPHORETIC DRUG DELIVERY
	 	February 21, 2003
	 	USPN 6,745,071; issued
	 

	 	SYSTEM
	 	 	 	June 1, 2004

 

 

	 	 	 	 	 	 	 
	File No.	 	Title	 	Filing Date	 	Status
	II. PATENTS ISSUED OUTSIDE U.S. (8)

	 
	 	 	 	 	 	 
	990322.EP

	 	CONTROLLED DOSAGE DRUG
	 	August 18, 1999
	 	Pat No. 1,115,454; issued
	 

	 	DELIVERY SYSTEM
	 	 	 	October 25, 2006
	 
	 	 	 	 	 	 
	20000315.EP

	 	RATE ADJUSTABLE DRUG
	 	October 4, 2000
	 	Pat. No. 1242142; issued
	 

	 	DELIVERY SYSTEM
	 	 	 	September 5, 2007
	 
	 	 	 	 	 	 
	20020208.EP.CIP

	 	DOSAGE CONTROL ELECTRODE
	 	September 16, 2005
	 	Pat. No. 1596931; issued
	 

	 	FOR IONTOPHORESIS DEVICE
	 	 	 	February 28, 2007
	 
	 	 	 	 	 	 
	20020208.CA.CIP

	 	DOSAGE CONTROL ELECTRODE
	 	August 31, 2005
	 	Pat. No. 2,512,352; issued
	 

	 	FOR IONTOPHORESIS DEVICE
	 	 	 	August 7, 2007
	 
	 	 	 	 	 	 
	20020208.KR.CIP

	 	DOSAGE CONTROL ELECTRODE
	 	August 19, 2005
	 	Pat. No. 0745233; issued
	 

	 	FOR IONTOPHORESIS DEVICE
	 	 	 	July 26, 2007
	 
	 	 	 	 	 	 
	20030061.AU

	 	IONTOPHORETIC DRUG DELIVERY
	 	August 11, 2005
	 	Pat. No. 2003267229; issued
	 

	 	SYSTEM
	 	 	 	March 20, 2008
	 
	 	 	 	 	 	 
	20030061.CA

	 	IONTOPHORETIC DRUG DELIVERY
	 	August 31, 2005
	 	Pat. No. 2,512,368; issued
	 

	 	SYSTEM
	 	 	 	December 19, 2006
	 
	 	 	 	 	 	 
	20030061.KR

	 	IONTOPHORETIC DRUG DELIVERY
	 	August 19, 2005
	 	Pat. No. 0735939; issued
	 

	 	SYSTEM
	 	 	 	June 28, 2007

 

 

	 	 	 	 	 	 	 
	File No.	 	Title	 	Filing Date	 	Status
	III. PENDING U.S. PATENTS

	 
	 	 	 	 	 	 
	20020208.CIP

	 	DOSAGE CONTROL ELECTRODE
	 	August 15, 2005
	 	 
	 

	 	FOR IONTOPHORESIS DEVICE	 	 	 	 
	 
	 	 	 	 	 	 
	20030304.ORI

	 	ABUSE POTENTIAL REDUCTION
	 	January 23, 2004	 	 
	 

	 	SYSTEM FOR ABUSABLE SUBSTANCE	 	 	 	 
	 

	 	DOSAGE FORM	 	 	 	 
	 
	 	 	 	 	 	 
	20050269.ORI

	 	TRANSDERMAL SYSTEMS FOR
	 	April 22, 2005	 	 
	 

	 	THE DELIVERY OF THERAPEUTIC	 	 	 	 
	 

	 	AGENTS INCLUDING GRANISETRON	 	 	 	 
	 

	 	USING IONTOPHORESIS	 	 	 	 
	 
	 	 	 	 	 	 
	20051390.ORI

	 	TRANSDERMAL SYSTEMS FOR THE
	 	December 21, 2007	 	 
	 

	 	DELIVERY OF ANESTHETIC AGENTS	 	 	 	 
	 

	 	FOR THE SUSTAINED PAIN MANAGEMENT	 	 	 	 
	 

	 	OF WOUNDS AND SURGICAL REPAIRED INCISIONS	 	 	 	 
	 
	 	 	 	 	 	 
	20070604.PRO

	 	TRANSDERMAL METHODS AND
	 	August 28, 2007	 	 
	 

	 	SYSTEMS FOR THE DELIVERY OF	 	 	 	 
	 

	 	CORTICOSTEROID COMPOUNDS	 	 	 	 
	 
	 	 	 	 	 	 
	IV. PATENTS PENDING OUTSIDE U.S.

	 
	 	 	 	 	 	 
	990322.JP

	 	CONTROLLED DOSAGE DRUG
	 	August 18, 1999	 	 
	 

	 	DELIVERY SYSTEM	 	 	 	 
	 
	 	 	 	 	 	 
	990322.JP.DIV

	 	CONTROLLED DOSAGE DRUG
	 	August 18, 2006	 	 
	 

	 	DELIVERY SYSTEM	 	 	 	 
	 
	 	 	 	 	 	 
	20000315.JP

	 	RATE ADJUSTABLE DRUG
	 	July 1, 2002	 	 
	 

	 	DELIVERY SYSTEM	 	 	 	 
	 
	 	 	 	 	 	 
	20000315.JP.DIV

	 	RATE ADJUSTABLE DRUG
	 	August 25, 2006	 	 
	 

	 	DELIVERY SYSTEM	 	 	 	 
	 
	 	 	 	 	 	 
	20020208.AU.CIP

	 	DOSAGE CONTROL ELECTRODE
	 	August 11, 2005	 	 
	 

	 	FOR IONTOPHORESIS DEVICE	 	 	 	 
	 
	 	 	 	 	 	 
	20020208.CN.CIP

	 	DOSAGE CONTROL ELECTRODE
	 	October 21, 2005	 	 
	 

	 	FOR IONTOPHORESIS DEVICE	 	 	 	 

 

 

	 	 	 	 	 	 	 
	File No.	 	Title	 	Filing Date	 	Status
	20020208.JP.CIP

	 	DOSAGE CONTROL ELECTRODE
	 	August 19, 2005
	 	 
	 

	 	FOR IONTOPHORESIS DEVICE	 	 	 	 
	 
	 	 	 	 	 	 
	20030061.CN

	 	IONTOPHORETIC DRUG DELIVERY
	 	October 21, 2005	 	 
	 

	 	SYSTEM	 	 	 	 
	 
	 	 	 	 	 	 
	20030061.EP

	 	IONTOPHORETIC DRUG DELIVERY

SYSTEM
	 	September 13, 2005	 	 
	 
	 	 	 	 	 	 
	20030061.JP

	 	IONTOPHORETIC DRUG DELIVERY
	 	August 19, 2005	 	 
	 

	 	SYSTEM	 	 	 	 
	 
	 	 	 	 	 	 
	20030304.EP

	 	ABUSE POTENTIAL REDUCTION
	 	January 20, 2005	 	 
	 

	 	IN ABUSABLE SUBSTANCE DOSAGE	 	 	 	 
	 

	 	FORM	 	 	 	 
	 
	 	 	 	 	 	 
	20030304.JP

	 	ABUSE POTENTIAL REDUCTION
	 	January 20, 2005	 	 
	 

	 	IN ABUSABLE SUBSTANCE DOSAGE	 	 	 	 
	 

	 	FORM	 	 	 	 
	 
	 	 	 	 	 	 
	20050269.AU

	 	TRANSDERMAL SYSTEMS FOR
	 	March 24, 2006	 	 
	 

	 	THE DELIVERY OF THERAPEUTIC	 	 	 	 
	 

	 	AGENTS INCLUDING GRANISETRON	 	 	 	 
	 

	 	USING IONTOPHORESIS	 	 	 	 
	 
	 	 	 	 	 	 
	20050269.CA

	 	TRANSDERMAL SYSTEMS FOR
	 	March 24, 2006	 	 
	 

	 	THE DELIVERY OF THERAPEUTIC	 	 	 	 
	 

	 	AGENTS INCLUDING GRANISETRON	 	 	 	 
	 

	 	USING IONTOPHORESIS	 	 	 	 
	 
	 	 	 	 	 	 
	20050269.CN

	 	TRANSDERMAL SYSTEMS FOR
	 	March 24, 2006	 	 
	 

	 	THE DELIVERY OF THERAPEUTIC	 	 	 	 
	 

	 	AGENTS INCLUDING GRANISETRON	 	 	 	 
	 

	 	USING IONTOPHORESIS	 	 	 	 
	 
	 	 	 	 	 	 
	20050269.EP

	 	TRANSDERMAL SYSTEMS FOR
	 	March 24, 2006	 	 
	 

	 	THE DELIVERY OF THERAPEUTIC	 	 	 	 
	 

	 	AGENTS INCLUDING GRANISETRON	 	 	 	 
	 

	 	USING IONTOPHORESIS	 	 	 	 

 

 

	 	 	 	 	 	 	 
	File No.	 	Title	 	Filing Date	 	Status
	20050269.KR

	 	TRANSDERMAL SYSTEMS FOR
	 	March 24, 2006
	 	 
	 

	 	THE DELIVERY OF THERAPEUTIC	 	 	 	 
	 

	 	AGENTS INCLUDING GRANISETRON	 	 	 	 
	 

	 	USING IONTOPHORESIS	 	 	 	 
	 
	 	 	 	 	 	 
	20060655.WP

	 	TRANSDERMAL METHODS AND
	 	April 12, 2007	 	 
	 

	 	SYSTEMS FOR THE DELIVERY OF	 	 	 	 
	 

	 	ANTI-MIGRAINE COMPOUNDS	 	 	 	 

 

 

EXHIBIT 2

Form of Patent Assignment Agreement

(See attached)

 

 

PATENT ASSIGNMENT AGREEMENT

     WHEREAS, Travanti Pharma, Inc., a Minnesota corporation whose principal place of business is
located at 2520 Pilot Knob Road, Suite 100, Mendota Heights, MN 55120 (“Assignor”), and NuPathe,
Inc., a Delaware corporation whose principal place of business is 227 Washington Street, Suite 200,
Conshohocken, PA 19428 (“Assignee”), are parties to that certain Asset Purchase and License
Agreement dated as of July 8, 2008 (the “Purchase Agreement”);

     WHEREAS, pursuant to said Purchase Agreement, Assignor has agreed to enter into this Patent
Assignment Agreement (the “Patent Assignment”) to assign and transfer the Anti-Migraine Patent (as
such term is defined in the Purchase Agreement) and statutory invention registration listed in the
attached Schedule A (collectively, the “Assigned Patent”) to Assignee; and

     WHEREAS, Assignor is the owner of all rights, titles and interests throughout the Territory
in, under and to the inventions claimed by the Assigned Patent (“Patent Rights”), and Assignee is
desirous of acquiring all of said Assigned Patent and Patent Rights.

     NOW, THEREFORE, in consideration of the payment by Assignee to Assignor of the sum of Five
Million Five Hundred Thousand Dollars ($5,500,000), and for other good and valuable consideration,
the receipt of which is hereby acknowledged, the parties hereto agree as follows:

          1. Assignor does hereby assign to Assignee, all right, title and interest in and to the
Assigned Patent and Patent Rights, including any and all causes of action, rights and remedies
arising under such Assigned Patent or Patent Rights prior to or after the effective date of this
Patent Assignment, and any divisions, reissues, continuations, continuations-in-part, renewals,
extensions, revisions and foreign counterparts of such Assigned Patent and Patent Rights to be held
and enjoyed by Assignee for its own use and benefit and for the use and benefit of its successors,
assigns or other legal representatives to the end of the term for which such Assigned Patent and
Patent Rights are granted or reissued as fully and entirely as the same would have been held and
enjoyed by Assignor if this assignment had not been made.

          2. Assignor authorizes and empowers Assignee or its nominees to invoke and claim for the
Assigned Patent and Patent Rights any and all other form of protection, the benefit of the right of
priority provided by the International Convention for the Protection of Industrial Property, as
amended, or by any convention which may henceforth be substituted for it, and to invoke and claim
such right of priority without further written or oral authorization from Assignor.

          3. Assignor hereby consents that a copy of this assignment shall be deemed a full legal and
formal equivalent of any assignment, consent to file or like

 

 

document which may be required in the United States or any foreign country for any purpose, and
more particularly but without limitation in proof of the right of Assignee or its nominees to claim the aforesaid benefit of the right of priority provided by the International Convention
for the Protection of Industrial Property, as amended, or by any convention which may henceforth be
substituted for it.

          4. Assignor hereby authorizes the respective officials whose duty it is to issue patent rights
or other forms of industrial property protection to issue to or as requested by Assignee, in
accordance with the terms of this Patent Assignment, the Assigned Patent and Patent Rights, and to
issue any and all letters patent and Patent Rights resulting from the Assigned Patent and Patent
Rights and from any and all reissues, re-examinations, divisions, continuations, renewals,
extensions, continuations-in-part, revisions, and foreign counterparts thereof, such that all
letters patent and other Patent Rights resulting from the Assigned Patent and Patent Rights, and
any worldly rights not expressly referenced herein on the inventions, vest in and accrue to
Assignee.

          5. Assignor hereby represents and warrants that it has the full right and power to convey the
entire rights, titles and interests herein assigned and that it has not executed and will not
execute any agreement in conflict herewith.

          6. At the request of Assignee, Assignor agrees to execute and deliver all documents, papers,
instruments and assignments, and to perform any other reasonable acts Assignee may require, in
order to vest in Assignee all of Assignor’s rights, titles, and interests in and to the Assigned
Patent and the Patent Rights, including but not limited to execution and delivery of such documents
with respect to particular Assigned Patent in particular countries in the Territory, delivery of
all Documents (as the term is used in the Purchase Agreement), and the transfer of power of
attorney and other indicia of authority pertaining to the Assigned Patent, delivery of
instructions to Foreign Associates to look to Assignee for all further instructions relating to the
Assigned Patent, and the provision of evidence to support any of the foregoing in the event such
evidence is deemed necessary by Assignee, to the extent such evidence is in the possession or
control of Assignor.

          7. Assignor hereby irrevocably makes, constitutes and appoints Assignee, and authorizes and
empowers Assignee to make, constitute and appoint any officer or agent of Assignee as Assignee may
select in its exclusive discretion, as such Assignor’s true and lawful attorney-in-fact, with full
power of substitution and with the absolute power and authority to take any and all action and to
execute thereafter any and all applications, documents, papers, filings and instruments which
Assignee deems necessary or desirable to accomplish the purposes of this Assignment. Assignor
hereby ratifies and confirms all that such attorney shall lawfully do or cause to be done by virtue
hereof.

[No further text on this page]

 

 

     IN WITNESS WHEREOF, Assignor has executed this Patent Assignment as of the date first set
forth above.

	 	 	 	 	 
	 	ASSIGNOR: 	 
	 	 	 
	 	TRAVANTI PHARMA, INC. 	 
	 	 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 	 	Place of Execution: 

	 
	 

STATE OF                          §

COUNTY OF                      §

     I, the undersigned Notary Public, do hereby attest that before me on this day personally
appeared                     , known to me to be the person whose name is subscribed to the foregoing
instrument, who acknowledged to me that he executed the same for the purposes and consideration
therein expressed, in the capacity therein stated and as the act and deed of said corporation.

     GIVEN UNDER MY HAND and seal of office this                      day of                     , 2008.

	 	 	 	 	 
	 	 	 
	 	  	
 	 
	 	 	Notary Public in and for the State of                      	 
	 	 	My Commission Expires: 	 
	 

(Seal)

 

 

     ACKNOWLEDGED AND ACCEPTED this Patent Assignment from Assignor as of the date first set forth
above.

	 	 	 	 	 
	 	ASSIGNEE: 	 
	 	 	 
	 	NUPATHE, INC. 	 
	 	 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 	 	Place of Execution: 

	 
	 

STATE OF                          §

COUNTY OF                      §

     I, the undersigned Notary Public, do hereby attest that before me on this day personally
appeared                     , known to me to be the person whose name is subscribed to the foregoing
instrument, who acknowledged to me that he executed the same for the purposes and consideration
therein expressed, in the capacity therein stated and as the act and deed of said corporation.

     GIVEN UNDER MY HAND and seal of office this                      day of                     , 2008.

	 	 	 	 	 
	 	 	 
	 	  	
 	 
	 	 	Notary Public in and for the State of                      	 
	 	 	My Commission Expires: 	 
	 

(Seal)

 

 

Schedule A

Patent

	 	 	 	 	 	 	 	 	 
	Title	 	Application No.	 	Patent No.	 	Filing Date	 	Grant Date
	Transdermal Methods

	 	PCT/US07/09000
	 	 
	 	April 12, 2007
	 	 
	and Systems for the

	 	WO/2007/120747	 	 	 	 	 	 
	Delivery of
	 	 	 	 	 	 	 	 
	Anti-Migraine
	 	 	 	 	 	 	 	 
	Compounds Related
	 	 	 	 	 	 	 	 
	Applications

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}]]